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ABSTRACT 
 
The interaction between folate and methylenetetrahydrofolate reductase (MTHFR) 
gene is an example of a strong gene-nutrient interaction. MTHFR 677C→T 
polymorphism may be associated with homocysteine in the modulation of the 
cardiovascular disease (CVD). Additionally, the interaction between the polymorphism 
and folate has been linked to a protective effect in individuals with colorectal cancer 
(CRC). The aim of this work is to assess the possible association between MTHFR 
677C→T polymorphism, CVD and CRC, modified by folate and homocysteine. The 
predictive response of CRC patients carrying MTHFR 677C→T polymorphism, treated 
with 5-fluorouracil, is also briefly examined, along with the current strategies to inhibit 
tumours, involving MTHFR gene as a target. Studies were found by searches of 
electronic literature for papers up to October 2014 using the terms “MTHFR 677C→T 
polymorphism” “folate,” “cardiovascular disease,” “homocysteine,” “colorectal cancer” 
and “chemotherapy”. Collected studies were mainly observational, randomised 
controlled trials, meta-analyses and systematic reviews, approximately from the last 15 
years. The association between MTHFR 677C→T polymorphism and CVD was found, 
although results from folate supplementation trials demonstrated no benefit in CVD. 
High supply of folate and TT genotype carriers may have a lower risk to develop colon 
cancer in some populations. The type and amount of folate, along with its 
supplementation when carcinogenesis is already stablished may increase the risk for 
CRC. MTHFR 677C→T polymorphism seems to be associated with better prognosis 
and less toxicity in 5-fluorouracil monotherapy. MTHFR inhibition technique shows 
promising results as an anti-cancer therapy. Findings are inconsistent to recommend 
folate supplementation in TT genotype carriers with CVD and CRC. A genetic and 
environmental risk assessment for CRC risk in primary care, regarding folate and 
MTHFR 677C→T polymorphism is worth considering. Further research on 
combinatory MTHFR polymorphisms and riboflavin effect, could help clarify the 
association between MTHFR 677C→T polymorphism, folate and disease. 
 
Keywords:  
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RESUMO 
 
Pensa-se que a variante do enzima codificado pelo polimorfismo MTHFR 677C→T 
possa estar associado à homocisteína e consequentemente, associado ao risco de 
doenças cardiovasculares (CVD); assim como a associação entre o folato e a mesma 
variante polimórfica possa proteger contra o cancro colorretal (CRC). O objetivo deste 
trabalho é correlacionar o polimorfismo MTHFR 677C→T com CVD e CRC, associado 
ao folato e à homocisteína. A resposta terapêutica ao 5-fluorouracil em pacientes com 
CRC e com o polimorfismo é também, brevemente analisada, juntamente com as atuais 
estratégias de inibição de tumores, envolvendo MTHFR. Os estudos foram identificados 
por pesquisa eletrónica de referências bibliográficas publicadas até outubro de 2014, 
usando as terminologias: “polimorfismo MTHFR 677C→T”, “folato”, “doença 
cardiovascular”, “homocisteína”, “cancro colorretal” e “quimioterapia”. 
Compreenderam principalmente estudos observacionais, clínicos randomizados, meta-
análises e revisões sistemáticas dos últimos 15 anos. A associação entre o polimorfismo 
e CVD foi encontrada, embora os resultados de estudos com suplementação de folato 
não demonstrem benefício, em CVD. O elevado consumo de folato e o genótipo TT 
parecem estar associados a menor risco de cancro do cólon. O tipo e quantidade de 
folato, juntamente com a fase da carcinogénese na qual se inicia a suplementação do 
mesmo podem estar relacionados com o aumento do risco de CRC. O polimorfismo 
parece estar associado a um melhor prognóstico e menor toxicidade em tratamentos com 
5-fluorouracil. A técnica de inibição de MTHFR mostra resultados promissores como 
terapia anticancerígena. Os resultados são inconsistentes para recomendar suplementos 
de folato em indivíduos TT. Testes de avaliação da interação gene-ambiente, em relação 
ao folato e ao polimorfismo referido podem ser justificáveis, em indivíduos em risco de 
CRC. Mais estudos que combinem os polimorfismos do MTHFR e que analisem o 
efeito da riboflavina, ajudariam a compreender a associação entre o polimorfismo 
MTHFR 677C→T, o folato e a doença.  
 
Palavras-chave:  
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RESUMÉ 
 
Interaktionen mellem methylentetrahydrofolat reduktase (MTHFR) genet og folat er 
et eksempel på en stærk gen-næringsstof interaktion. MTHFR 677C → T polymorfi kan 
være associeret med homocystein i modulering af kardiovaskulær sygdom (KVS). 
Derudover er interaktionen mellem polymorfi og folat blevet associeret med en 
beskyttende effekt hos personer med kolorektal cancer (KRC). Målet med dette speciale 
er at vurdere den mulige sammenhæng mellem MTHFR 677C → T polymorfi, KVS og 
KRC modificeret af folat og homocystein. Den prædiktive reaktion hos KRC- patienter, 
som bærer MTHFR 677C → T polymorfi behandlet med 5-fluorouracil-baseret 
kemoterapi er også kortvarigt undersøgt sammen med de nuværende strategier til at 
hæmme tumorer, der involverer MTHFR som et mål. Studier blev fundet ved søgninger 
i elektronisk litteratur for artikler frem til oktober 2014 ved brug af søgetermerne 
"MTHFR 677C → T polymorfi", "folat", "hjertekarsygdom", "homocystein", 
"kolorektal cancer" og "kemoterapi". Indsamlede studier var hovedsageligt 
observationsstudier, randomiserede kontrollerede studier, metaanalyser og systematiske 
reviews, alle hovedsageligt fra de sidste 15 år. Associationen mellem MTHFR 677C → 
T polymorfi og KVS blev fundet, selvom resultater fra folat-supplement studier ikke 
viste forbedring for KVS. Hypertension i TT-genotype bærere synes justerbare med 
riboflavin-tilskud. Høj forsyning af folat og TT-genotype bærere kan have en lavere 
risiko for at udvikle tyktarmskræft i visse populationer. Type og mængde af folater kan 
sammen med karcinogenes fase øge risikoen for KRC. MTHFR 677C → T polymorfi 
synes at være associeret med bedre prognose og mindre toksicitet i 5-fluorouracil 
monokemoterapi. MTHFR-hæmning-teknik viser lovende resultater som en anticancer-
terapi. Resultaterne er inkonsistente i forhold til at anbefale folat-supplement i TT-
genotype bærere med KVS og KRC. For visse populationer er gen-miljø vurderingstests 
vedrørende folat og MTHFR 677C → T polymorfi værd at overveje for KRC 
risikoindivider. Yderligere forskning på kombinatoriske MTHFR-polymorfier og 
riboflavin kunne bidrage til at afklare associationen mellem MTHFR 677C → T 
polymorfi, folat og sygdom.  
 
Nøgleord: 
MTHFR 677C → T polymorfi; folat; hjertekarsygdom; kolorektal cancer  
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INTRODUCTION 
 
Multifactorial diseases, such as cancer and cardiovascular disease are expanding 
globally in prevalence and mortality. Most of these conditions have a multifactorial 
inheritance due to genetics, but lifestyle and environmental factors, such as diet can 
prompt their start. Therefore, understand the interaction between genetics and diet is a 
major step in controlling multifactorial diseases (Lobo, 2008).  
 
Extensive investigation upon the past 20 years has disclosed important aspects about 
one-carbon metabolism and its regulation. One-carbon metabolism plays a critical role 
in both DNA methylation and DNA synthesis, through the association of folate and 
methionine metabolism, along with homocysteine catabolism, being folate the central 
cofactor, ensuring the correct flow of carbon moieties (Ikeda et al., 2012). 
 
The interconnection between folate and methionine cycle happens with the 
irreversibly reaction catalysed by methylenetetrahydrofolate reductase (MTHFR) that 
produces 5-methyltetrahydrofolate, a methyl donor in homocysteine remethylation to 
methionine, directing the folate pool towards methylation reactions, in detriment of 
DNA synthesis (Bailey & Gregory, 1999).  
 
However, some polymorphisms from the MTHFR gene have been linked to the 
impairment of the enzyme function. MTHFR 677C→T polymorphism is the most 
significant, and accumulating evidences have shown that this variant of the MTHFR 
gene is associated with many disease outcomes, particularly in cardiovascular disease 
and colorectal cancer (Kennedy et al., 2012; Klerk et al., 2002). Individuals with the 
677C→T homozygous variant (TT genotype) have lower MTHFR activity than 
heterozygotes (CT genotype) or homozygotes wild-type (CC genotype), and under 
conditions of low dietary folate, people with the TT genotype can have elevated plasma 
homocysteine concentrations because not enough folate is metabolized to 5-
methyltetrahydrofolate (Trabetti, 2008).    
 
A number of molecular mechanisms of homocysteine have been suggested, and the 
underlying common pathogenic mechanisms are predominantly associated with 
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vascular injury (Brustolin, Giugliani, & Felix, 2010). Due to its impact on vascular 
tissues, homocysteine has been hypothesised as an independent risk factor for 
cardiovascular disease. However, homocysteine concentrations are positively correlated 
with many other cardiovascular risk factors, such as dyslipidemia, hypertension, 
sedentary lifestyle and unhealthy diet that can be potential confounders in 
epidemiological studies (Ueland & Loscalzo, 2012). Thus, many evidences suggest that 
homocysteine is more an epiphenomenon of vascular disease, rather than a casual factor 
(Brattström & Wilcken, 2000). 
 
By contrast, several findings indicate that high intake of folate and the TT genotype 
are associated with reduced risk of colorectal cancer, compared to low intake of folate, 
heterozygous and wild-type genotypes (Kennedy et al., 2012).  However, a dual effect 
of folate in colorectal cancer has been recently reported, suggesting a possible 
enhancement of carcinogenesis (Castillo-Lancellotti, Marí & Dagach, 2012). 
Consequently, folate supplementation effect has been vastly evaluated on lowering 
homocysteine concentrations in cardiovascular disease, through several large-scale 
interventional trials and in colorectal cancer patients, mainly through observational 
studies (Clarke et al., 2010; Hubner & Houlston, 2008). 
 
The fact that MTHFR enzyme influences the concentrations of substrates involved in 
some antimetabolites chemotherapy supports the idea that MTHFR 677C→T 
polymorphism might have a pharmacogenetic role in predicting the efficacy and the 
toxicity of some cancer drugs (Chua et al., 2009). Additionally, emerging studies point 
to an alternative anti-cancer therapy targeting MTHFR enzyme (Stankova, Shang & 
Rozen, 2005).  
 
Overall, in the present thesis, the possible association between MTHFR 677C→T 
polymorphism, cardiovascular disease and colorectal cancer modified by the level of 
folate intake and homocysteine is reviewed, with regard to the observational studies, 
randomised controlled trials, meta-analyses and systematic reviews from the last 15 
years. The predictive clinical outcomes from MTHFR 677C→T polymorphism of 
colorectal cancer patients, treated with 5-fluorouracil chemotherapy is also briefly 
examined, as the current strategies to inhibit the growth of tumours, involving MTHFR 
gene as possible target. 
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CHAPTER I – ESSENTIAL BIOCHEMISTRY OF ONE-CARBON METABOLISM 
 
 1.1. OVERVIEW 
One-carbon metabolism can be understood as a biochemical network that regulates 
nutrient physiologic status, centred on folate and methionine. This process involves 
three major pathways: folate metabolism, cycle of methionine and transsulfuration 
pathway of homocysteine (Hcy) [Fig. 1]. In addition to folate, methionine and Hcy, 
other nutrients are required to maintain the flow of carbon units, such as pyridoxal 5'-
phosphate (PLP, vitamin B6), riboflavin (vitamin B2), cobalamin (vitamin B12), serine 
and betaine (Ikeda et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The terminology “one-carbon” refers to carbon moieties, such as methyl, methylene, 
methenyl and formyl units carried by folate coenzymes, essential for purine and 
thymidylate synthesis and, consequently, crucial for the preservation of genomic 
stability. Besides that, another function of one-carbon metabolism includes 
remethylation of Hcy in order to form methionine, the precursor of S-
adenosylmethionine (SAM). SAM is a methyl donor for a wide range of methylation 
reactions involving lipids, hormones, DNA, proteins, etc. (Hazra et al., 2009). 
Therefore, one-carbon metabolism nutrients and metabolites participate in multiple 
biological processes, such as epigenetics (through methylation), correct DNA synthesis 
(via regulation of nucleotide pools), vitamin and amino acid metabolism, and lipid 
Serine 
Betaine 
Choline 
 
Methionine cycle 
Transsulfuration 
pathway of Hcy 
 
Folate cycle 
Riboflavin 
PLP 
Cobalamin 
Figure 1. Inputs in one-carbon metabolism (adapted from: Locasale, 2013). 
PLP – pyridoxal 5'-phosphate 
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biosynthesis. In addition to biosynthesis and methylation, one-carbon metabolism plays 
a role in redox homeostasis (Locasale, 2013).  
 
The activity of enzymes involved in one-carbon metabolism is greater in the liver, 
followed by the pancreas and kidney. Moreover, one-carbon metabolism is highly 
compartmentalised in eukaryotic cells, with some studies suggesting that the 
compartmentalisation of folate coenzymes and one-carbon units are mechanisms of 
regulation for the entire process (Tibbetts & Appling, 2010). 
 
1.2. FOLATE CYCLE AND METABOLIC PATHWAY 
Folate is found mainly in leafy vegetables, justifying its name origin from the Latin 
word “folium”, which means “leaf”. This nutrient is included in the vitamin B complex 
and cannot be produced by humans. However, folate differs from other B vitamins 
because it serves as a catalytic substrate for the transfer of one-carbon units, playing a 
major role ensuring the equilibrium between redox and methylation status in the body, 
in addition to the synthesis of purine and thymidylates (Czeizel, Dudás, Vereczkey & 
Bánhidy, 2013). 
 
Using accurate terminology, folate refers to the family of substances containing a 
pteridine ring conjugate to both ρ-aminobenzoic acid and (poly)-glutamate(s) found in 
dietary food. They can be found in a reduced form linked to a polyglutamyl chain 
containing different numbers of glutamic acids depending on the type of diet (Ikeda et 
al., 2012).  
 
Polyglutamate residues are critical for the retention of folates in eukaryotic cells 
leading to efficient substrates for many folate-dependent enzymes in the one-carbon 
metabolism. Formyltetrahydrofolate synthetase is an example of that, the affinity of the 
enzyme for tetrahydrofolate (THF) with four or five glutamate residues is 150 times 
greater than for the monoglutamate form of THF (Fowler, 2001). 
 
The structure of folate derivatives varies from unsubstituted polyglutamyl THFs to 
various substituted one carbon forms of THF (e.g. 10-formyl-, 5, 10-methylene-, and 
predominantly 5-methylTHF). Nevertheless, the unsubstituted forms are poorly stable 
Folic acid, one-carbon metabolism, MTHFR polymorphisms and pathologies 
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due to the fragile bond between the C-9 and N-10 leading to a substituted pteridine, and 
ρ-aminobenzoylglutamate that carries no biologic activity. Even though the substitution 
of a carbon group at N-5 or N-10 lowers the tendency of breakage, the molecule is still 
vulnerable to oxidation, and, therefore, predisposed to inactivation (Brody & Shane, 
2001).  
 
Within the group of folate derivatives stands out folic acid, a synthetic compound not 
found in nature in significant quantities. Folic acid is fully oxidised, and used 
industrially as nutritional supplements in fortified foods, or for pharmaceutical 
purposes. In this form, the pteridine ring is not reduced, making the molecule more 
resistant to oxidative rearrangements (Hoffbrand & Weir, 2001). 
 
Summing up, folate from food differs from folic acid, mostly in three aspects: in 
additional glutamate residues, in reduction to di- or tetrahydroforms, and in additional 
single carbon units attached to N-5 or N-10 nitrogen atoms [Fig. 2] (Brody & Shane, 
2001; Ikeda et al., 2012). 
 
 
 
Figure 2. Structure of folic acid (a) and related compounds (b) (adapted from: Fowler, 2001). 
 
After ingestion, folic acid is rapidly absorbed, mainly in jejunum. Absorption occurs 
by active transport via the proton-coupled folate transporter (PCFT), and folic acid 
suffers a two-step reduction to dihydrofolate (DHF). Subsequently, DHF is converted in 
a) 
 
 
 
 
 
b) 
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THF by the enzyme dihydrofolate reductase (DHFR) in the presence of ascorbic acid. 
Folic acid appears to have a higher bioavailability than folate in food, about 80% or 
greater (Winkels et al., 2007).  
 
In contrast, the polyglutamyl chain from natural folates is removed in the brush 
border of the mucosal cells by folate conjugase, reducing the bioavailability of folate as 
much as 25–50% because the reaction is not complete. After, folate monoglutamate is 
absorbed by both passive diffusion and active transport via PCFT. Both folate 
monoglutamates and folic acid, in the form of THF, are methylated to 5-methylTHF by 
one-carbon metabolism enzymes and release to circulation, being 5-methylTHF the 
principal circulating form of folate (Ikeda et al., 2012). 
 
Peripheral cells take up 5-methylTHF via reduced folate carrier or folate receptor, 
and incorporate it into one-carbon metabolism, which then must be polyglutamated for 
cellular retention and one-carbon metabolism coenzyme function. Thus, the central 
folate acceptor molecule in the one-carbon cycle is a polyglutamyl form of THF (Bailey 
& Gregory, 1999). Therefore, 5-methylTHF must be converted to THF via methionine 
synthase, explained in more detail in the next section.  
 
The beginning of one-carbon metabolism via folate cycle starts with the conversion 
of THF into 5, 10-methyleneTHF. This reaction is a decisive step in the cycle, using the 
3-carbon of serine as a main carbon source. Serine can be originated from 3-
phosphoglycerate involved in glycolysis, or can also be directly imported from the 
extracellular environment by facilitated transport through amino acid transporters. The 
one-carbon unit is transferred from serine side-chain to THF via PLP-dependent serine 
hydroxymethyltransferase to form 5, 10-methylene-THF and glycine, in a reversible 
reaction (Locasale, 2013).  
 
5, 10-methyleneTHF can follow two different pathways depending on the cell needs: 
can enter methionine cycle via reduction to 5-methylTHF by the riboflavin-dependent 
enzyme MTHFR, or be metabolised in several one-carbon transfer reactions leading to 
the synthesis of thymidylates and purines [Fig. 3] (Blom & Smulders, 2011; Forges et 
al., 2007).  
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Figure 3. Simplified representation of the one-carbon metabolism pathway (Humpath.com - Human 
pathology, 2003). FR – folate receptor; RFC – reduced folate carrier; MTHFR – 
methylenetetrahydrofolate reductase; MTR – methionine synthase; MTRR – methyltetrahydrofolate-
homocysteine methyltransferase reductase; SHMT – serine hydroxymethyltransferase; MTHFD - 
methylenetetrahydrofolate dehydrogenase; TS – thymidylate synthase; GARFT – glycinamide 
ribonucleotide formyltransferase; AICARFT – 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase; DHFR – dihydrofolate reductase; THF – tetrahydrofolate; AdoHcy – S-(5′-
adenosyl)-L-homocysteine; AdoMet – S-adenosylmethionine.  
 
During the synthesis of thymidylates, the one-carbon group of 5, 10-methyleneTHF 
is donated to deoxyuridine monophosphate (dUMP), resulting in the formation of 
deoxythymidine monophosphate (dTMP) and dihydrofolate (DHF), reaction catalysed 
by the thymidylate synthase (TYMS). TYMS reaction is considered a limiting step in 
DNA synthesis, and, more importantly, reduces dUMP levels. Finally, DHFR catalyses 
the reduction of DHF back into THF (Forges et al., 2007).  
 
In the purines synthesis, 5, 10-methyleneTHF is catalysed by the trifunctional 
enzyme methyleneTHF dehydrogenase (MTHFD) that has formyltetrahydrofolate 
synthetase, methenylTHF cyclohydrolase and methyleneTHF dehydrogenase activities. 
This reaction originates 5, 10-methenylTHF, and, subsequently 10-formylTHF that can 
donate a formyl groups for purines biosynthesis (Blom & Smulders, 2011). 
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1.3. METHIONINE AND S-ADENOSYLMETHIONINE CYCLE  
Methionine is an essential sulfur-containing proteinogenic amino acid in humans and 
serves as the initiating amino acid in eukaryotic protein synthesis. It is an overly 
consumed amino acid in developed countries at about 60% over that is required to the 
organism. Methionine cycle serves to regulate cellular methylation through adequate 
supply of SAM, and is a source of glutathione, the cell principle antioxidant, enabling 
the redox buffering. Methionine cycle could not accomplish its function without being 
interconnected with folate cycle in a network implying more than twenty enzymes 
(Joint, 1998). 
 
The interconnection between folate and methionine cycle happens with the 
irreversibly conversion of 5, 10-methyleneTHF to 5-methylTHF, reaction catalysed by 
MTHFR, using NADPH or FAD, as reducing agents. MTHFR has a key role in one-
carbon metabolism by irreversibly directing one-carbon moieties to Hcy remethylation, 
rather than DNA synthesis [Fig. 4] (Crider, Yang, Berry & Bailey, 2012). The enzyme 
is a dimer with each monomer constituted by a catalytic domain that binds the FAD 
cofactor and folate, and a regulatory domain that binds SAM (Ulvik et al., 2007). 
 
After 5-methylTHF production, remethylation of Hcy to form methionine occurs via 
cobalamin–dependent methionine synthase, a ubiquitously expressed enzyme. 
Additionally, remethylation can happen as well via betaine-homocysteine-
methyltransferase (BHMT), mainly expressed in the liver and kidneys, the main organs 
storing large amounts of betaine, required as a methyl group donor (Obeid, 2013). 
 
Methionine synthase reaction involves the generation of a complex, 
cobalamin(I)methionine synthase, between cobalamin coenzyme, intermediate carrier of 
the methyl group, and methionine synthase, that binds to the methyl group of 5-
methyTHF to form methylcobalamin(III)methionine synthase. After transferring the 
methyl group to Hcy, and originating methionine, cobalamin(I)methionine synthase is 
reformed, being able to accept another methyl group from 5-methylTHF, restarting the 
cycle (Blom & Smulders, 2011).  
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Figure 4. Methionine metabolism (Lu & Mato, 2012). MAT – S-adenosylmethionine synthetase; 
BHMT – betaine-homocysteine-methyltransferase; MS – methionine synthase; AHCY – S-
adenosylhomocysteine hydrolase; MTHFR – methylenetetrahydrofolate reductase; MTs – 
methyltransferases; Me2-glycine – dimethylglycine; AdoMet – S-adenosylmethionine; AdoHcy – 
S-adenosyl-L-homocysteine; 5-MTHFR – 5-methyltetrahydrofolate;  
5, 10-MTHFR – 5,10-methylenetetrahydrofolate.  
 
 
Thus, 5-methylTHF is converted to THF closing the cycle of folate (Blom & 
Smulders, 2011). BHMT is an alternative pathway for the remethylation of Hcy, 
connecting the oxidative catabolism of choline to methionine metabolism. In this 
reaction, the methyl group is donated by betaine that is converted into dimethylglycine 
(Forges et al., 2007). Once remethylation of Hcy occurs, the resulting methionine is, 
either incorporated into proteins, or converted into SAM by S-adenosylmethionine 
synthetase (MAT) (Ikeda et al., 2012).  
 
SAM is the major methyl donor for most methyltransferases and is involved in 
numerous cellular reactions, including methylation of DNA, histone, proteins, synthesis 
of polyamines, binding to mRNA, methylation and synthesis of lipids, and antioxidants 
reactions (such as glutathione and taurine) [Fig. 5] (Mato & Lu, 2007). Thus, SAM is 
determinant for a wide range of biological processes, from membrane fluidity, gene 
expression, cell growth, differentiation, to suppression of cell division and apoptosis. 
 
In methylation reactions, SAM has a methyl group removed, resulting in S-
adenosylhomocysteine (SAH) a potent competitive inhibitor of many 
methyltransferases. Then, SAH can be hydrolysed to Hcy and adenosine [Fig. 4]. 
Physiologically, the biosynthesis of SAH is favoured, rather than its hydrolysis. The 
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reverse situation can happen if adenosine and Hcy are being rapidly eliminated, which is 
crucial to avoid accumulation of SAH (Lu & Mato, 2012). 
 
 
 
Figure 5. Structure of S-adenosylmethionine (Mato & Lu, 2007).  
CBS – Cystathionine-β-Synthase 
 
The effectiveness of the cycle depends on the replenishment of methyl groups in 
order to keep a proper concentration of SAM. Therefore, the remethylation of Hcy back 
to methionine and thus to SAM is essential for the cell survival (Joint, 1998). 
 
1.4. HOMOCYSTEINE METABOLISM AND TRANSSULFURATION PATHWAY 
Hcy is a thiol-containing non-proteinogenic amino acid exclusively originated from 
the demethylation of methionine. In most mammalian cells, Hcy can suffer different 
metabolic fates: 1) remethylation, which is the conversion to methionine by methionine 
synthase or BHMT, as described before in last section; 2) catabolism via 
transsulfuration pathway, where it is irreversibly converted to cysteine [Fig. 6]; 3) 
release into the extracellular medium (Brustolin, Giugliani, & Felix, 2010). However, 
when the remethylation pathway is saturated, or when cysteine is required, Hcy follows 
the transsulfuration pathway (Blom & Smulders, 2011). 
 
The transsulfuration pathway is an alternative mechanism to Hcy remethylation, and 
is the real mechanism by which methionine is catabolised, occurring in most tissues 
except in muscle and endothelium. Furthermore, transsulfuration pathway plays a role 
in the maintenance of the redox homeostasis, providing an endogenous route where Hcy 
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can be used for the generation of redox-controlling molecules, such as glutathione and 
taurine (Zhang et al., 2013).  
 
 
Figure 6. Transsulfuration pathway for homocysteine degradation and cysteine synthesis (Lu & 
Mato, 2012). CBS – cystathionine-β-synthase; CSE - cystathionine-γ-lyase. 
 
 
  
In the transsulfuration pathway, Hcy is condensed with serine in a β-replacement 
irreversible reaction of the hydroxyl group of serine by cystathionine-β-synthase (CBS) 
forming cystathionine, with release of a water molecule. CBS is a heme-containing 
enzyme that is subject to regulatory control, as it is the first and rate-limiting enzyme 
for the transsulfuration pathway (McBean, 2012). On the second step of the 
transsulfuration pathway, the resulting cystathionine, from CBS reaction, is then 
hydrolysed to cysteine, alpha-ketobutyrate (from the Hcy carbon chain), and ammonia 
(from the amino group of Hcy) by cystathionine-γ-lyase (CSE) [Fig. 6]. Both enzymes, 
CBS and CSE are dependent on PLP, the active form of vitamin B6. Alpha-ketobutyrate 
can suffer oxidative decarboxylation catalysed by pyruvate dehydogenase complex 
producing propionylcoenzyme A that can enter the tricarboxylic acid cycle. Cysteine 
can be used for the glutathione biosynthesis, and originate metabolites in mammals such 
as taurine, pyruvate, and hydrogen sulfide (Stipanuk & Ueki, 2011).  
 
The balance of transsulfuration depends on the quantity of prooxidants and 
antioxidants. The prooxidants increase the transsulfuration flux, while antioxidants 
decrease it. Some studies agree that redox regulation of the transsulfuration pathway 
occurs at the level of CBS, due to the heme portion that serves as a sensor for the 
oxidative medium (Brosnan & Brosnan, 2006). 
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Figure 7. Schematic representation of the MTHFR gene, located on chromosome 1p36.3. Exons are 
shown in black boxes. The two most investigated polymorphisms, 677C→T and 1298A→C, 
corresponding to the amino acid substitution A222V and E429A, respectively, are indicated above 
their corresponding exons (Trabetti, 2008). 
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2.1. CYTOGENETIC LOCATION 
MTHFR gene is located on the short (p) arm of chromosome 1 at position 36.3. 
(Trabetti, 2008). The majority of polymorphisms reported for MTHFR gene have a 
minor impact on enzymatic activity, with the exception of 677C→T and 1298A→C. 
MTHFR 677C→T and 1298A→C polymorphisms seem to be in linkage disequilibrium, 
with findings pointing to the appearance of 677 variant later than the 1298C variant on a 
chromosome harbouring 1298A. However, only MTHFR 677C→T polymorphism has 
been established to lower considerably serum folate and higher plasma homocysteine 
(Ulvik et al., 2007). 
 
 MTHFR 677C→T polymorphism is transmitted in an autosomal recessive way and 
is characterized by a point mutation at base pair 677 (exon 4) that converts a cytosine 
(C) into a thymine (T) leading to an amino acid substitution (alanine to valine) at codon 
222 in the MTHFR gene [Fig. 7] (Trabetti, 2008).   
 
 
 
 
 
 
 
 
 
 
 
 
The enzyme becomes thermolabile in homozygotes for the variant (TT genotype), 
with lower activity (50-60% at 37°C and nearly 65% at 46°C), leading to increased Hcy 
levels in individuals with low folate status. In heterozygotes (CT genotype), enzyme 
activity is in an intermediate range, and functions normally in wild-type homozygotes 
(CC genotype) (Leclerc, Sibani & Rozen, 2005).  
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Many conditions have been associated with MTHFR 677C→T polymorphism, such 
as birth defects, psychiatric disorders [Table 1], vascular disease and cancer (both 
discussed in the following chapters); supporting the idea, that folate supplementation 
could have a role in the treatment and prevention of those diseases (Gilbody Lewis & 
Lightfoot, 2007). The relationship between the MTHFR 677C→T polymorphism and 
disease involves several mechanisms, such as plasma Hcy (tHcy), DNA methylation 
and DNA synthesis (Ueland et al., 2001). 
 
Table 1. Results from studies relating diseases and MTHFR 677C→T polymorphism. 
Study / Authors Study type Results / Conclusions 
Psychiatric 
disorders (unipolar 
depression, anxiety 
disorders, bipolar 
disorder, and 
schizophrenia) 
 
Gilbody, Lewis & 
Lightfoot, 2007 
Meta-analysis 
• For unipolar depression and the fixed-effects odds 
ratio (OR) for homozygote variants (TT) versus the wild 
type (CC) was 1.36 (95% confidence interval (CI): 1.11, 
1.67), on 1,280 cases and 10,429 controls. 
• For schizophrenia the fixed-effects OR for TT versus 
CC was 1.44 (95% CI: 1.21, 1.70), on 2,762 cases and 
3,363 controls.  
• For bipolar disorder the fixed-effects OR for TT versus 
CC was 1.82 (95% CI: 1.22, 2.70), on 550 cases and 
1,098 controls.  
 
 This meta-analysis demonstrates an association 
between the MTHFR 677C→T polymorphism and 
depression, schizophrenia, and bipolar disorder, raising 
the possibility of the use of folate in treatment and 
prevention. 
Neural tube defects 
(spina bifida aperta or 
encephalocele) 
 
Kirke et al., 2004 
Case-control 
 
Cases: 397 
individuals with 
spina bifida 
aperta (380) or 
encephalocele 
(17)  
 
Controls: 1000 
newborn 
• The heterozygous genotype is associated with an 
increased risk of neural tube defects (OR 1.52; p= 
0.0015).  
• Risk is also raised for the homozygous TT genotype 
(OR 2.56; p< 0.0001). 
• CT genotype is responsible for at least as many neural 
tube defects in the population as the TT genotype (14.9% 
νs 11.3%), because a much greater proportion of the 
population are heterozygous for this allele. 
 
 CT genotype needs to be considered as a risk factor 
for other conditions where homozygosity has been 
shown to be associated with increased risk.  
 
2.2. POPULATION GENETICS 
The worldwide distribution of MTHFR 677C→T polymorphism varies extensively 
among regions and populations. The frequency of the T allele ranges from 1% or less in 
Blacks from sub-Saharan, but increases substantially, up to 20%, among Caucasians and 
Chinese (Botto & Yang, 2000). In Europe, the prevalence of the TT genotype increase 
towards south direction, from low values in the north (4-7% in Finland, Helsinki, 
Chapter II – MTHFR 677C→T polymorphism: general aspects 
 
25 
Northern Netherlands, and Russia), to intermediate values (8-10%) in France and 
Hungary, to higher values in Southern Europe (12-15% in Spain and Northern Italy), 
peaking in southern Italy (20-26% in Campania and Sicily). In North America, the 
frequency of TT homozygotes increase from Western Canada to Southeastern United 
States, reaching a peak in Mexico [Fig. 8] (Wilcken et al., 2003).  
 
 
 
Figure 8. Prevalence of homozygous TT genotype among newborns by area and ethnic background 
(Wilcken et al., 2003). 
 
 
The prevalence of MTHFR 677C→T polymorphism varies considerably in China 
through a geographic gradient. For MTHFR 677C→T, the frequencies of the T allele 
and the TT genotype are notably higher in the north (63.1% and 40.8%, respectively) 
compared to the south (24.0% and 6.4%, respectively) (Yang et al., 2013). 
 
The explanation for the differences found geographically and ethnically is thought to 
involve, in part, gene-nutrient interactions, between MTHFR 677C→T gene 
polymorphism and folate as suggested by Guéant-Rodriguez et al (2006). The authors 
reported Mexico City and Sicily as having the highest concentration of folate, the 
lowest rate of folate deficiency and the areas where influence of the TT genotype on 
tHcy was the lowest. Additionally, these areas exhibit the highest T allele frequency. In 
fact, the main resemblance concerning those two populations is their characteristic diet, 
richer in fresh fruit and vegetables, which are wide sources of folate. In another hand, 
they found a high prevalence of folate deficiency in West Africa, where the lowest 
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frequency of the T allele was registered. Additionally, in West Africa, the genotype 
influence on tHcy was the most evident; the majority of individuals with the T allele 
had elevated tHcy. These data indicate a possible interaction between the environment 
and genetic pressure and suggest that TT genotype may confer a survival advantage in 
populations with adequate dietary folate consumption (Guéant-Rodriguez et al, 2006).  
 
In fact, other studies indicate that heterozygous or homozygous mutant genotypes 
with adequate folic acid consumption may have, in certain circumstances, a selective 
advantage over wild-type genotype, which may explain the current observed variability 
in its frequency in different populations. Further facts that support this hypothesis are 
the beneficial effect to heterozygotes during times of starvation and the decreased risk 
of 677C→T homozygotes for colon cancer (Schneider, Rees, Liu & Clegg, 1998), 
which is going be examined in the last chapter.  
 
2.3. RELATIONSHIP WITH PLASMA HOMOCYSTEINE 
Hcy concentrations are regulated by many factors such as the cofactors cobalamin, 
PLP, folate and enzymes implicated in methionine metabolism. When discrepancies 
between Hcy production and catabolism take place, tHcy can increase. Impairments in 
Hcy metabolism can derive from various nutritional and/or congenital disorders, such as 
MTHFR 677C→T polymorphism (Medina, Urdiales, & Amores‐Sánchez, 2001).  
 
Most of the tHcy is found in the oxidised form. Only 1–2% are present in its reduced 
form. Approximately 20% occurs as acid-soluble free Hcy in a form of homocysteine-
cysteine mixed disulfide and homocystine (a dimer of Hcy). Approximately 70% to 
80% circulate bounded to plasma proteins; the great majority travels linked to the 
cysteine of albumin, its main carrier in plasma. However, current data suggest that 
approximately 10%–30% of protein bound Hcy and cysteine are linked to globulins. 
The total tHcy is the sum of all protein-bound and free forms containing a thiol group 
(Amorim et al., 2011). 
 
In healthy individuals, concentrations of Hcy oscillate between 5 and 15 µmol/L. 
Hyperhomocysteinemia (HHcy) is the presence of an abnormally elevated concentration 
of plasma or serum, and can be distinguished by category, including cause, prevalence 
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and severity [Table 2]. HHcy is dependent on genetic, lifestyle, gender, being higher in 
men than in women and age, increasing from 10.8 µmol/L at age 40-42 up to 12.4 
µmol/L between 65-67 years. Moreover, HHcy is observed in approximately 5% of the 
general population, and it is implicated in several morphological and physiological 
changes that are thought to increase the risk for many disorders, including vascular and 
neurodegenerative diseases, autoimmune disorders, birth defects, diabetes, renal 
disease, osteoporosis, neuropsychiatric disorders, and cancer (Brustolin, Giugliani, & 
Felix, 2010). 
 
Table 2. Classification of hyperhomocysteinemia (Brustolin, Giugliani & Felix, 2010). 
Severe hyperhomocysteinemia 
tHcy levels at all times (31 to >100 µmol/L) caused, for example, by deficiencies in CBS, MTHFR, 
or in enzymes of cobalamin metabolism. 
Mild hyperhomocysteinemia 
Moderately high tHcy levels (15-30  µmol/L) under fasting conditions; reflects impaired Hcy 
methylation (folate, cobalamin or moderate enzyme defects, e.g., thermolabile MTHFR) 
Post-methionine load 
Abnormal increase in tHcy (>15  µmol/L) after a methionine load (100 mg/kg); reflects impaired Hcy 
transsulfuration (heterozygous CBS defects, PLP deficiency) 
 
Apart from that, some findings reveal that elevated tHcy is associated with 
administration of certain medications, including antiepileptic drugs, methotrexate, 
antihypertensive, lipid-lowering and antidiabetic drugs (Malinow, Bostom & Krauss, 
1999).  
 
Ham et al (2014) conducted a study with 2,912 participants to assess the link 
between medication use, tHcy levels, and the potential mediation by serum vitamin B12 
and folate [Table 3]. The only cases with higher mean Hcy levels were observed in 
users vs. non-users for diuretics, high-ceiling sulphonamide diuretics, medication acting 
via the renin-angiotensin system and metformin. Non-selective β-blocker use was 
associated with lower mean Hcy levels and only this association was mediated by an 
underlying association with vitamin B12 and folate levels. Nonetheless, the associations 
between tHcy levels and medication use appears to be unassertive, suggesting that 
medication use is unlikely to contribute to clinically relevant changes in tHcy levels. 
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 Table 3. Associations between medication use and homocysteine levels in an older population, and 
potential mediation by vitamin B12 and folate (Ham et al., 2014). 
Medication group Results and possible mechanisms 
• Diuretics in general 
• High-ceiling sulphonamide 
diuretics 
• Agents acting via the renin-
angiotensin system 
 
• Small but significant positive association with tHcy. 
• Largely independent of vitamin B12 and folate levels. 
• Diuretic use has previously been shown to be associated with 
higher tHcy, possibly through decreasing folate levels.  
• High-ceiling sulphonamides are known as potent inhibitors of 
the reabsorption of electrolytes in the kidneys, resulting in 
reduced water reabsorption into the blood and thus increased 
water excretion. This alteration in fluid status, or mild 
dehydration, might cause the observed relative increase of the 
tHcy.  
• Non-selective β-blocker 
• Inverse significant association with tHcy was observed. 
• Characterised by an underlying association with vitamin B12 
and folate levels. 
• How non-selective b-blockers may affect vitamin B12 and folate 
levels is still unknown. 
• Thiazides 
• Selective β-blockers  
• Statins 
• Sulphonylurea derivatives 
• No association was observed with tHcy, especially for 
metoprolol. 
• Metformin 
• Higher tHcy. 
• Relationship between metformin and tHcy was independent of 
vitamin B12 and which became slightly stronger after including 
folate levels. 
• Metformin increases insulin sensitivity, and potentially insulin 
levels are involved. Nevertheless, the literature reports 
contradictory findings, as both insulin sensitivity as well as 
insulin resistance were associated with higher tHcy. 
• Proton pump inhibitor 
• Histamine H2 receptor antagonist 
• Methotrexate 
• Acetylsalicylic acid 
• Theophylline 
• L-dopa 
• Lack of association with tHcy.  
• Anticonvulsants  
• Lack of association with tHcy. 
• The association has been consistently reported in the literature. 
• Anticonvulsant drugs may reduce folate levels and particularly 
in combination with the MTHFR TT genotype, this may result in 
elevated tHcy.  
• The discrepancy between these findings and other studies may 
be explained by the non-significant interaction with the MTHFR 
polymorphism and the low frequency of folate deficiency in the 
population studied. 
• Combination of medication 
groups significantly associated 
with higher homocysteine level 
• No additive effect of the association was observed.  
• There is no literature regarding a potential additive effect of a 
combination of medication use on tHcy.  
• Nevertheless, because of multiple drug use, older individuals 
are more prone to unintended drug effects of which increased 
tHcy might have been one. 
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2.3.1. MOLECULAR MECHANISMS OF HOMOCYSTEINE 
Endothelial cells participate in the regulation and preservation of vascular system and 
are extremely susceptible even to a mild increase in Hcy concentration. This sensitivity 
may be justified by the fact, that human endothelial cells do not express active form of 
CBS, and consequently, cannot initiate Hcy catabolism through transsulfuration 
pathway [Fig. 9]. Thus, a number of molecular mechanisms of Hcy have been 
suggested, and the underlying common pathogenic mechanisms are predominantly 
associated with vascular injury [Fig. 10] (Perła-Kaján, Twardowski & Jakubowski, 
2007). 
 
 
Figure 9. Simplified homocysteine metabolism (adapted from: Esse et al., 2012). AdoMet – S-
adenosylmethionine; AdoHcy – S-adenosyl-L-homocysteine; MAT – S-adenosylmethionine 
synthetase; Met – methionine; Cys – cysteine; Hcy – homocysteine. 
 
One of the pathogenic mechanisms proposed includes oxidative damage of the 
endothelium through nitric oxide (NO) suppression. The excess of Hcy leads to 
inhibition of NO synthase, by reducing the catabolism of its inhibitor, and, 
consequently, decreasing NO bioavailability. Under normal conditions, NO detoxify 
plasma from Hcy through formation of S-nitro-Hcy. However, in presence of large 
amounts of Hcy, and subsequent inhibition of NOS, NO cannot neutralize the excess, 
leading to the auto-oxidation of Hcy to homocystine with release of toxic free radicals 
to the vascular endothelium (Stühlinger et al., 2001). 
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Additionally, Hcy may affect glutathione peroxidase activity, changing the 
dissemination of reactive oxygen species. Endothelial glutathione peroxidase catalyses 
the reduction of hydrogen and lipid peroxides to the equivalent alcohol, avoiding the 
oxidative inactivation of NO. The mechanism by which Hcy may act is thought to 
involve the downregulation of glutathione peroxidase expression (Yilmaz, 2012).  
 
 
 
 
Figure 10. Molecular mechanisms of homocysteine (adapted from: Brattström & Wilcken, 2000; 
Heneghan & Sultan, 2008; Medina, Urdiales & Amores‐Sánchez, 2001; Perna et al., 2003; 
Stühlinger et al., 2001; Wang, Siow, & Karmin, 2001; Yilmaz, 2012; Zhang et al., 2012). 
 
Hcy is also known as thrombogenic agent, boosting platelet aggregation, acting on 
the coagulation cascade, directly inducing a synergistic pathway with other risk factors. 
It activates coagulation factor V, X, and XII, inhibits protein C and cell-surface 
thrombomodulin, and modulates tissue plasminogen activator, through annexin II (an 
endothelial receptor) (Perna et al., 2003). 
 
HHcy can have a direct impact on DNA methylation, leading to modifications in the 
gene expression, affecting both endothelial cells and smooth muscle cells. An increase 
in tHcy generates a growth in the intracellular concentration of SAH that can bind to 
methyltransferases with higher affinity than SAM. However, SAH is a potent inhibitor 
of DNA methyltransferases, affecting cell homeostasis (Castro et al., 2003). Several 
studies suggest that hypomethylation processes, due to of HHcy, induce proliferation of 
vascular smooth muscle cells, resulting in a decrease of the vessel calibre (Zhang et al., 
2012).  
 
Hyperhomocysteinemia 
Mechanisms 
•Nitric oxide suppression 
•Downregulation of glutathione peroxidase 
•Protein thiolation 
•Protein homocysteinylation 
•Promotion of coagulation 
•Oxidation of LDL  
•Hypomethylation processes 
•Promotion of inflammation and 
atherosclerosis 
Vascular lesion 
? 
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Another molecular pathogenic mechanism of Hcy is believed to involve the 
formation of adducts with disulfide linkages with sulphydryl residues of proteins, in a 
reaction known as thiolation [Fig. 11]. Moreover, the detrimental effect of Hcy in 
proteins may be caused by the formation of Hcy thiolactone, leading to protein 
homocysteinylation, when transsulfuration or remethylation pathways are compromised. 
Both occurrences can lead to an irreversible damage of the enzymatic activity and 
denaturation of proteins, such as haemoglobin, low-density lipoproteins (LDL) and 
plasma proteins (Medina, Urdiales & Amores‐Sánchez, 2001). 
 
 
 
Figure 11. Generation of reactive homocysteine thiolactone (adapted from: Medina, Urdiales & 
Amores‐Sánchez, 2001). 
 
 
As a result of the vascular injury effect, Hcy has been frequently referred as “the 
cholesterol of the 21
st century”. HHcy can produce vascular injury by increasing the 
oxidation of LDL within vascular cells and tissues. LDL aggregates of Hcy in the 
bloodstream can be taken up by macrophages, originating foam cells, the precursors of 
atherosclerotic plaques. Within these plaques, Hcy modifies the oxidative and synthetic 
processes of artery wall cells, propagating plaque formation (Heneghan & Sultan, 
2008). 
 
Hcy has been associated with the promotion of inflammation and atherosclerosis, 
activating NF-κB responsible for the induction of chemokines and interleukins 
expression. Yet, Hcy can activate monocytes proliferation, inducing cytokines 
expression and inhibiting the expression of MMIF (Wang, Siow, & Karmin, 2001). 
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However, the origin HHcy is yet to be understood. Brattström and Wilcken (2000) 
suggest that, in reality, HHcy is more an epiphenomenon of vascular disease, having a 
minor role in the vascular damage. They hypothesised that the decline in renal function 
can be the actual cause of HHcy in vascular disease patients. Risk factors for vascular 
disease, such as atherogenesis and hypertension, frequently progress in a discrete way 
over the time before the appearance of clinically evident vascular episodes. Therefore, 
atherogenesis and hypertension can conduct to renal impairment, affecting the clearance 
of Hcy. As matter of fact, the existence of vascular illnesses would promote the raise of 
Hcy in plasma through the impairment of renal function. 
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CHAPTER III – MTHFR 677C→T POLYMORPHISM AND CARDIOVASCULAR RISK 
 
3.1. MTHFR 677C→T POLYMORPHISM, HOMOCYSTEINE AND CARDIOVASCULAR RISK 
Cardiovascular disease (CVD) or heart disease is a group of illnesses that involves 
the heart and/or the blood vessels, leading mostly to cardiac disease, vascular diseases 
of the brain and kidney, and peripheral arterial disease (Kelly, 2010). The concerns 
about CVD are reasonable due to its considerable high mortality rate, being the 
primarily worldwide cause of death. Additionally, the overall CVD is estimated to cost 
the EU economy almost €196 billion a year (Nichols et al., 2012). The causes 
underlying CVD are diverse and multifactorial, but atherosclerosis and hypertension are 
the most common causes, defined by genetic and environmental aspects, such as gene-
gene and gene-environment interactions (Sabetisoofyani, Larson & Watson, 2010).   
 
As discussed in the last chapter, HHcy is cogitated by many researchers to grant a 
mild vascular risk alone, and to increase the risk of vascular lesions in association with 
other factors. Therefore, the attention given to cardiovascular risk and mild increase of 
circulating Hcy has been motivating investigators to establish a connection between 
MTHFR 677C→T polymorphism and CVD risk (Clarke et al., 2012; Xuan et al., 2011).   
 
The metabolic phenotype of low concentrations of folate and tHcy elevated over 
25% in individuals with the TT genotype compared with those with the CC genotype 
has been vastly assessed in Mendelian randomisation studies (Brattström, Wilcken, 
Öhrvik & Brudin, 1998). If a gene variant is responsible for higher tHcy levels, random 
allocation of this gene during conception produces a randomised trial of low versus high 
Hcy from birth on [Fig. 12]. Many studies revealed increased cardiovascular risk in 
individuals with the TT genotype compared with those carrying the wild-type (Smulders 
& Blom, 2011). 
  
MTHFR 677C→T polymorphism was initially pointed as a possible risk factor for 
CVD in Canadians and afterwards it was also described in Japanese, in Italians, in 
Chinese, and in English population (Sazci et al., 2006). If proved such association, the 
high frequency of the T allele within a certain population could serve to emphasize 
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recommendations concerning nutrient consumption, and avoidance of other 
cardiovascular risk factors. 
  
 
 
Figure 12. Principle of Mendelian randomisation as applied to hyperhomocysteinemia. 
Essential for the validity of the model is the absence of arrows between the gene and confounders, as 
well as the absence of an arrow (a direct association not dependent on the risk factor) between the 
gene and the disease (Smulders & Blom, 2011). 
 
Several MTHFR 677C→T polymorphism studies, including retrospective and 
prospective studies, suggest that the association between the polymorphism and CVD is 
causal, stating HHcy as the underlying mechanism (Wald, Law & Morris, 2002). 
However, the debate about this topic has intensified in the beginning of the 21
st
 century 
with several studies showing discordant results. Many studies advocate that mild HHcy 
associated with MTHFR 677C→T polymorphism is not high enough to be an 
independent risk factor for the development of CVD. Thus, although the association 
between tHcy concentrations and CVD has been already demonstrated, the causality is 
not yet established (Brattström, Wilcken, Öhrvik & Brudin, 1998).  
 
3.2. CORONARY HEART DISEASE 
Several meta-analyses, using all data published concerning the association between 
the risk of coronary heart disease (CHD) and MTHFR 677C→T polymorphism, have 
been conducted to aid the assessment of causality [Table 4]. In 2002, a meta-analysis, 
including single participant data from all case-control studies on the polymorphism and 
risk of CHD, involved data from MTHFR 677C→T genotype, levels of tHcy, folate, and 
other cardiovascular risk factors. The results pointed to a relation between TT genotype 
and increased CHD risk, when folate status were low, suggesting an interaction between 
the MTHFR 677C→T polymorphism and folate status, holding the hypothesis that 
HHcy could be the triggering mechanism (Klerk et al., 2002).  
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However, results of CVD studies do not seem to be concordant for the overall 
population. In 2011, another meta-analysis on published studies, studied the association 
between the polymorphism and risk of myocardial infarction (MI), and found 
association only for Caucasians (Xuan et al., 2011). 
 
Even though collected evidences have shown an association between HHcy and 
CHD, there is a strong divergence in results, with studies supporting the idea that HHcy 
might be just a consequence of CHD. Additionally, the divergence is magnified when 
the causality between MTHFR 677C→T polymorphism and risk of CHD is 
hypothesised. An updated meta-analysis of unpublished studies on MTHFR 677C→T 
polymorphism and CHD performed in 2012 found that the additional CHD risk in TT 
compared to CC genotype carriers was only 2%, a negligible increase, certainly 
coincidental. The stratification of the study populations by folate status showed, as well, 
no evidence that T allele had an extra CHD risk compared to the wild-type [Table 4] 
(Clarke et al., 2012).  
  
Table 4. Results from studies relating coronary heart disease and MTHFR 677C→T polymorphism. 
Study / Authors Study type Sample Results 
Coronary heart 
disease 
 
Klerk et al., 2002 
Meta-analysis 
of 40 
published and 
unpublished 
studies 
11,162 
cases 
 
12,758 
controls 
 Individuals with the TT genotype had a 16% 
(OR, 1.16; 95% CI, 1.05-1.28) higher odds of 
CHD than those with the CC genotype. 
 Significant heterogeneity between the results 
obtained in European populations (OR, 1.14; 95% 
CI, 1.01-1.28) compared with North American 
populations (OR, 0.87; 95% CI, 0.73-1.05). 
Myocardial 
Infarction 
 
Xuan et al., 2011 
Meta-analysis 
of 30 
published 
studies 
8,140 
cases 
 
10,522 
controls 
 Significant association was found between 
MTHFR 677C→T polymorphism and risk of MI 
(OR, 1.183; 95% CI, 1.076–1.300). 
 The same association was found in overall 
Caucasians (OR, 1.139; 95% CI: 1.007–1.288) 
and young/middle-aged (<50 years) Caucasians 
(OR, 1.275; 95% CI, 1.077–1.509). 
 No associations were detected between MTHFR 
677C→T polymorphism and the risk of MI in 
elderly male or female Caucasians, East Asians, 
South Asians, and African-Americans. 
Coronary heart 
disease 
 
Clarke et al., 2012 
Meta-analysis 
of 19 
unpublished 
studies 
48,175 
cases 
 
67,961 
controls 
 The case-control CHD OR and 95% CI 
comparing TT vs CC homozygotes was 1.02, and 
0.98–1.07, respectively (p= 0.28). 
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Figure 13. MTHFR 677C→T 
frequencies of CC, CT and TT 
genotypes. Frequencies were 38.5, 35.7 
and 25.5% in the VTE group and 41.4, 
43.2 and 15.5% in the controls, 
respectively. In the two groups, the level 
of Hcy in subjects with the TT genotype 
or CT genotype was higher than that in 
subjects with the CC genotype. The 
plasma level of Hcy in the VTE group 
(13.05±2.37 μmol/l) was significantly 
higher than that in the control group 
(11.94±2.03 μmol/l, P<0.001) (Yin et 
al., 2012). 
 
3.3. VENOUS THROMBOSIS 
The specific mechanism of susceptibility for venous thrombosis remains unclear. 
Interest in the genetic basis of venous thrombosis was enhanced by discover of genes 
with a possible effect in thrombophilia, such Leiden V factor, prothrombin G20210A 
and MTHFR 677C→T polymorphism (Yin et al., 2012). 
 
Due to HHcy association with venous thrombosis, MTHFR 677C→T polymorphism 
has been proposed as a genetic risk factor candidate for venous thrombosis. 
Consequently, several studies have suggested that the effect of MTHFR 677C→T 
polymorphism on venous thrombosis is only perceptible in particular minor groups with 
other predisposing genetic or environmental factors or, in contrast, in minor groups in 
which conventional risk factors for venous thrombosis are missing. Based on this 
premise, one could suggest that in clinical practice, measurement of Hcy levels (and the 
assessment of folate levels) would be reasonable for individuals with unsolved 
idiopathic, persistent venous thrombosis, or venous thrombosis occurring at early age or 
at an uncommon site (Den Heijer, Lewington & Clarke, 2005).  
 
In 2012, a study examined the possible relation between MTHFR 677C→T 
polymorphism and venous thromboembolism (VTE) [Table 5]. The results showed that 
the frequency of T alleles and TT carriers was significantly higher in patients compared 
with that of the healthy controls. In addition, the plasma levels of Hcy in the VTE group 
were higher compared with those in the control group. The results of the study imply 
that HHcy and MTHFR 677C→T polymorphism could be considered risk factors for 
VTE [Fig. 13] (Yin et al., 2012).  
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Joachim and colleagues (2013) conducted a study to assess the prevalence of HHcy 
and MTHFR variant in a pediatric population with VTE, and the association with 
thrombus outcome. Subjects were enlisted in an institution-based prospective cohort of 
children with VTE. The prevalence of HHcy or MTHFR variant was not amplified in 
comparison with the control group. Plasma Hcy did not change between those with CC 
genotype versus MTHFR 677C→T heterozygotes or homozygotes, and adverse 
thrombus outcomes were not associated either. 
 
In concordance with the previous study, a meta-analysis evaluating risk factors for 
venous thrombosis showed the same lack of association. The study used the Multiple 
Environmental and Genetic Assessment including subjects with first venous thrombotic 
event, deep vein thrombosis of either the leg or pulmonary embolism [Table 5]. In this 
study, MTHFR 677C→T polymorphism was not associated with the risk of venous 
thrombosis. Stratification by risk factors did not provide evidence of an association in 
specific groups. Since genotype distributions did not differ between case and control 
groups, there was no excess risk of venous thrombosis associated with MTHFR 
677C→T polymorphism. Consequently, based on this study, routine testing of MTHFR 
677C→T genotype as part of a thrombophilia evaluation with venous thrombosis would 
not be justified (Bezemer et al., 2007). 
 
Table 5. Results from studies relating venous thrombosis and MTHFR 677C→T polymorphism. 
Authors Study type Sample Results 
Yin et al., 
2012 
Population
-based 
case-
control 
440 cases 
 
440 controls 
 The plasma levels of Hcy in the VTE group (13.05±2.37 
µmol/l) were significantly higher compared with those in 
the control group (11.94±2.03 µmol/l, P<0.001). 
 Compared with the CC genotype, the TT genotype was 
significantly correlated with an increased risk of VTE 
(OR, 1.753; 95% CI, 1.215–2.529; P=0.003). 
 In the VTE group (F=106.051; P<0.001), the level of 
Hcy in subjects with the CT+TT genotype (14.49±2.51 
μmol/l) was significantly higher than that in subjects with 
the CC genotype (11.35±1.57 μmol/l, P<0.001). 
Bezemerl 
et al., 
2007 
Population
-based 
case-
control 
4375 cases 
 
4856 controls 
 The TT genotype was present in 440 patients (10%) and 
517 control subjects (11%), and the CT genotype in 1891 
patients (43%) and in 2094 control subjects (43%). 
 Stratification by known risk factors for venous 
thrombosis, such as V Leiden, prothrombin 20210G→A, 
family history, age, and presence of predisposing factors 
provided no evidence of an association in specific groups. 
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3.4. ISCHEMIC AND HAEMORRHAGIC STROKE 
The MTHFR 677C→T polymorphism has been associated, as well, to ischemic and 
haemorrhagic stroke in many studies but not in others [Table 6]. In 2010, a study 
evaluated the MTHFR 677C→T polymorphism in ischemic and haemorrhagic stroke 
patients in a Northern Indian population. Despite the elevated tHcy found in TT 
genotype ischemic stroke patients, MTHFR 677C→T gene polymorphism was 
associated with neither haemorrhagic nor ischemic stroke (Somarajan, Kalita, Mittal & 
Misra, 2011). However, recent meta-analyses suggest that the T allele of the MTHFR 
677C→T polymorphism is associated with increased risk of haemorrhagic stroke (HS) 
and ischemic stroke (IS) [Table 6]. These results, if confirmed, are significant for the 
genetic epidemiology, diagnosis, treatment and prevention of HS and ARE (Kang et al., 
2013; Li & Qin, 2014). 
 
Table 6. Results from studies relating stroke and MTHFR 677C→T polymorphism. 
Study / 
Authors 
Study type Sample Results 
Ischemic stroke 
and 
Intracerebral 
haemorrhage 
(ICH) 
 
Somarajan et 
al., 2007 
Case–control 
Cases: 
207 IS 
215 ICH 
 
188 controls 
 The frequency of the CC genotype in controls 
was 68.6%, CT in 28.7% and TT in 2.7%. It was 
75.3%, 20.5% and 4.2% in ICH and 66.2%, 39.4% 
and 2.4% respectively in IS. 
 The frequency of these genotypes as well as 
allele frequency was not different in IS, ICH as 
compared to controls 
 Allele was more frequent in IS compared to ICH. 
 Hcy level was higher in IS patients with variant 
genotype. 
Haemorrhagic 
stroke 
 
Kang et al., 
2013 
Meta-
analysis  
of 15 case-
control 
studies 
2034 cases 
 
4485 controls 
 Significant associations between the MTHFR 
677C→T polymorphism and the risk of HS were 
observed in dominant (OR, 1.611, 95% CI, 1.336–
1.942), codominant (OR, 1.500, 95% CI, 1.330–
1.692), and recessive (OR, 1.695, 95% CI, 1.409–
2.038) models. 
Ischemic stroke 
 
Li & Qin, 2014  
Meta-
analysis  
of 19 case-
control 
studies 
2223 cases 
 
2936 controls 
 Statistically significant association with IS was 
identified for allele T (OR = 1.28; 95% CI, 1.17–
1.40, P < 0.00001). 
 Marginally significant association was detected 
with genotype CT (OR = 1.13; 95% CI: 1.01–127; 
P = 0.04) and genotype (OR = 1.43; 95% CI: 1.20–
1.70; P < 0.001). 
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A possible mechanism linking MTHFR 677C→T polymorphism and stroke events 
would be through elevated tHcy inducing endothelial dysfunction, mostly through 
coagulative effect in IS and rupture of microaneurysms in HS (Li et al., 2003). It was 
also postulated that elevated tHcy could cause, initially, IS and later, HS (Sazci et al., 
2006).  
 
3.5. CAN LOWERING HOMOCYSTEINE LEVELS REDUCE CARDIOVASCULAR RISK? 
An approach that could disclose the uncertainty around TT genotype, HHcy and 
CVD triangle would be to carry out several trials that evaluate the decrease of 
cardiovascular risk or the protective effect in TT genotype when tHcy level is reduced 
by supplementation of folate. If folate supplementation were demonstrated to reduce 
cardiovascular risk, this would be of considerable importance for public health and 
clinical practice. However, the majority of follow-up studies on the assessment of 
therapeutic intervention with folic acid-based vitamin supplements has indicating no 
beneficial effect in CVD prevention (Schwammenthal & Tanne, 2004).  
 
A daily dose of folic acid ranging 0.5 and 5 mg was associated with a 25% decrease 
in tHcy levels addressed in a meta-analysis of the short-term trials. This decrease in 
tHcy, accomplished with folic acid supplements, is similar to the variation in tHcy 
levels between TT and CC genotypes. Despite the positive results in some observational 
studies, a great part of interventional trials firmly contests any satisfactory result of 
lowering Hcy concentrations with folic acid treatment on CVD (Den Heijer, Lewington 
& Clarke, 2005). 
 
 Recent meta-analyses of randomised trials on the impact of lowering tHcy level by 
vitamin B supplementation on CVD showed that even with the decrease of 25% in tHcy 
no beneficial effect was found on the progression of the disease [Table 7] (Clarke et al., 
2010). 
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Table 7. Results from studies relating folate supplementation and MTHFR 677C→T polymorphism. 
Authors Study type Sample Results 
Clarke et al., 2010 
Meta-analysis 
of 8 large, 
randomised, 
placebo-
controlled trials 
37 485 
individuals at 
increased risk 
of 
cardiovascular 
disease 
 Folate supplementation led to an average 
of 25% reduction in Hcy levels 
 During a median follow-up of 5 years, 
folate supplementation had no significant 
effects on vascular outcomes, with an OR 
of 1.01 (95% CI, 0.97-1.05) for major 
vascular events; OR, 1.03 (95% CI, 0.97-
1.10) for major coronary events, and 0.96 
(95% CI, 0.87-1.06) for stroke.   
Clarke et al., 2012 
Meta-analysis of 
10 large-scale 
placebo-
controlled trials 
50,378 
individuals 
 Little or no effect on the 5 years 
incidence of CHD (OR, folate vs placebo, 
1.02; 95% CI, 0.96–1.08). 
 
3.6. POSSIBLE EXPLANATIONS FOR DISCREPANCIES AMONG STUDIES  
Sample dimension, linkage disequilibrium between polymorphisms, nutrition status, 
setting, and study design could be responsible for the discrepancy [Fig. 14]. Population 
specificity might play a role, because different groups of patients may have various sets 
of genetic factors that predispose to the disease, stressing the importance of ethnicity 
and genetic background (Yin et al., 2012). Specific alleles of candidate genes can be 
deeply correlated with the disease in one population, while in another this connection 
can be low because of other genetic factors or particular interactions between genetic 
and non-genetic factors (Trabetti, 2008). 
 
The geographical inconsistency of results may be as well attributed to the higher 
folate intake in certain countries. The impact of the polymorphism on tHcy levels 
depends largely on the folate intake. Consequently, if dietary folate is high, the 
expression of the TT phenotype is diminished, Hcy is less increased and so the risk of 
CVD is improbable (Wald, Law & Morris, 2002). For instance, the venous thrombosis 
risk estimated for TT genotype, obtained from studies carried out in North America, 
differed from those carried out in Europe and elsewhere, which may be explained by the 
higher dietary intake of folate and riboflavin in North America compared to Europe 
(Den Heijer, Lewington & Clarke, 2005). 
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Another reason might be due to discrepancies in study design. The clustering of 
additional risk factors among cases in case-control studies may introduce bias toward a 
higher risk estimate than in population-based studies (Yin et al., 2012). Thus, several 
well-established standard risk factors, such as, sex, age, smoking, blood pressure, 
cholesterol level, and sedentary habits might be associated with tHcy and may confound 
the relation between tHcy and CVD (Brattström et al., 1998). Relatively small case-
control studies may not have the statistical power to adjust and fully eliminate the 
effects of those risk factors on tHcy concentration. In addition, study heterogeneity 
reflected by the different selection of patients and control subjects, and occasional 
incomplete information on Hcy levels and folate status can be a source of discrepancies 
(Trabetti, 1998).  
 
 
Figure 14. Possible explanations for positive and negative association between MTHFR 677C→T 
polymorphism, homocysteine and cardiovascular disease among studies (adapted from: Brattström 
et al., 1998; Clarke et al., 2012; Den Heijer, Lewington & Clarke, 2005; Haynes & Clarke, 2012; 
Trabetti, 1998; Wald, Law & Morris, 2002; Yin et al., 2012). 
 
Authors suggest that apart from the common methodological problems, such as 
sampling, stratification, and analysis of cases and controls, the different outcomes of 
MTHFR 677C→T polymorphism studies might reveal the impact of publication bias 
[Fig. 14] (Haynes & Clarke, 2012). Mendelian randomisation meta-analyses of 
unpublished genetic epidemiology datasets are a helpful solution to assess the impact of 
publication bias on controversial topics, since it is not materially affected by publication 
bias. Majority of meta-analysis of unpublished datasets about MTHFR 677C→T 
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among  
MTHFR 677C→T 
polymorphism 
studies  
Sample 
dimension 
Linkage 
disequilibrium 
between 
polymorphisms 
Nutrition  Environment 
Study 
design 
Publication 
bias 
Folic acid, one-carbon metabolism, MTHFR polymorphisms and pathologies 
 
42 
polymorphism suggested no association between lowering tHcy and decrease risk in 
CVD (Clarke et al., 2012).  
 
Although the majority of randomised controlled trials suggest no benefit from 
lowering tHcy with folate supplementation, in the prevention of CVD, some other 
hypotheses where given to explain these results [Fig. 15] (Clarke et al., 2012). The 
absence of benefit from lowering tHcy, in the prevention of CVD registered in some 
randomized trials might be due to the fact that they are carried out in regions with 
established policies of population folate supplementation, which minimizes the effect 
expected from of the interventional trials (Holmes et al., 2011). 
 
Another reason might be based on the aspirin reducing or negating the anti-platelet 
effect of lowering tHcy in the trials. Based on this assumption, folate would have a part 
in the primary prevention of CVD, when aspirin is not administrated routinely, but not 
in secondary prevention, when it is routine. Thus, the negative trial evidence on CVD 
should not weaken the positive evidence from the MTHFR 677C→T polymorphism 
studies and erroneously lead to a conclusion that there is no role for folate in preventing 
CVD (Wald, Morris & Wald, 2011).  
 
Moreover, the power of some of arguments against can be questioned because HHcy 
and TT genotype could also have opposite effects on processes related to CVD. The TT 
genotype may autonomously modulate CVD risk, being independent from Hcy, through 
the distribution of folates in the direction of purine and pyrimidine biosynthesis. If this 
assumption is confirmed, the application of Mendelian randomisation studies into the 
association of MTHFR 677C→T polymorphism, Hcy and CVD [Fig. 12] has to be 
subject of further analysis to assess its real validity (Ueland et al., 2000). 
 
By contrast, some of the studies have suggested that B vitamins treatment might 
promote CVD [Fig. 15]. Trials of lowering Hcy concentrations are based, mainly, on 
prescription of folic acid and one of the main functions of folate metabolism is to 
provide one-carbon building blocks for the synthesis of purines and pyrimidine, 
increasing the DNA synthesis. Consequently, although high amounts of folic acid may 
be beneficial through the Hcy lowering, a secondary effect of folic acid use may prompt 
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atherosclerotic plaque progression, through vascular proliferation and inflammation 
(Blom & Smulders, 2011). 
 
 
Figure 15. Possible explanations for negative results from studies of folate supplementation, 
MTHFR 677C→T polymorphism and reduction of cardiovascular risk (adapted from: Blom & 
Smulders, 2011; Holmes et al., 2011; Ueland et al., 2000; Wald, Morris & Wald, 2011). 
 
Current guidelines recommend that patients with the TT genotype, with normal tHcy 
should be reassured that there is no current evidence of increased risk for venous 
thrombosis related to their MTHFR status, common reasons for which clinical testing is 
performed. A patient, who is homozygous for the MTHFR 677C→T polymorphism but 
also with elevated Hcy, may be at mildly elevated risk for venous thrombosis. The 
patient can also be reassured that there is no evidence of any association with 
homozygosity and mortality, from CVD. Furthermore, when an individual is 
homozygous for the polymorphism, it is suitable to assess some of the recognised 
associations, possible risks, highlighting that the effects have been small, the absolute 
risks are probable low, and it may even be established in the future that there is no 
increase above population risk (Hickey, Curry & Toriello, 2013). 
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3.7. NEW PERSPECTIVES: HYPERTENSION AND RIBOFLAVIN 
Hypertension, considered one of the major risk factors of CVD, is a condition where 
systolic and diastolic blood pressure reach 140/90 mmHg or higher. Reducing blood 
pressure values to normal addresses great improvements to the incidence and outcome 
of CV events. Apart from the traditional risk factors, understanding the role of genetic 
factors that might prompt hypertension has been a major challenge for researchers 
(McNulty, Strain & Ward, 2014). 
 
In recent years, many studies have found an association between the MTHFR 
677C→T polymorphism and hypertension, suggesting that CVD patients with TT 
genotype have significantly higher blood pressure. In 2014, a meta-analysis found a 
significant association between the MTHFR 677C→T polymorphism and hypertension, 
supporting the evidence that individuals with the TT genotype are susceptible to 
hypertension, compared with those with other genotypes [Table 8] (Yang et al., 2014).  
 
Additionally, was observed that 63% of patients with the TT genotype, being treated 
with one or more antihypertensive agents, failed to achieve the goal blood pressure 
(<140/90mmHg), indicating that the therapeutic effect of some specific antihypertensive 
drugs is unlikely to be accomplished in patients with the TT genotype [Table 8] 
(Horigan et al., 2010). 
 
The mechanism through which the MTHFR 677C→T polymorphism affects blood 
pressure is not yet completely defined, although reduced levels of riboflavin have been 
already suggested as possible cause. Riboflavin is the precursor of the coenzyme FAD, 
a cofactor for MTHFR enzyme. The variant enzyme becomes less active due to its 
tendency to separate from FAD (McNulty, Strain & Ward, 2014).  
 
Low levels of riboflavin in association with the TT genotype would conduct to a 
decrease in enzymatic function in cells including those of the arterial system, resulting 
in impaired vascular function leading to hypertension. Vascular concentrations of 5-
methylTHF (the active form of folate), an important regulator of NO, were found to be 
reduced in patients with the TT genotype (Wilson et al., 2012). 
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Blood pressure was found to be highly responsive to riboflavin, especially in patients 
with the MTHFR 677C→T polymorphism. A randomised trial investigated the 
sensitivity of blood pressure to riboflavin supplementation in hypertensive individuals 
with the TT genotype, without overt CVD. The results showed that riboflavin 
supplementation could decrease blood pressure more efficiently than current 
antihypertensive drugs, predominantly in individuals with the TT genotype. 
Consequently, the achievement of goal blood pressure (≤140/90 mm Hg) in this 
genetically susceptible group may be significantly improved with the supplementation 
of riboflavin in addition to antihypertensive medication (Wilson et al., 2013). 
 
The mechanism underlying riboflavin effect is based on its corrective function on 
MTHFR enzyme in cells. Some researchers believe that riboflavin may interact with 
MTHFR to influence blood pressure independent from tHcy, and elevated tHcy may 
only be a marker of decreased MTHFR activity in cells rather than being the cause 
associated with hypertension (Horigan et al., 2010).  
 
Table 8. Results from studies relating hypertension, riboflavin supplementation and MTHFR 677C→T 
polymorphism. 
Authors Study type Sample Results 
Yang et al., 2014 
Meta-analysis 
of 27 studies 
5,418 cases 
 
4,997 controls 
 A significant association between the 
MTHFR 677C→T polymorphism and 
hypertension was found under the allelic 
(OR, 1.32; 95% CI, 1.20‑ 1.45), dominant 
(OR, 1.39; 95% CI, 1.25‑ 1.55), recessive 
(OR, 1.38; 95% CI, 1.18‑ 1.62), 
homozygote (OR, 1.59; 95% CI, 
1.32‑ 1.92), and heterozygote (OR, 1.32; 
95% CI, 1.20‑ 1.45) genetic models. 
 A strong association was also revealed 
in subgroups, including Asian, Caucasian 
and Chinese. 
Horigan et al., 2010 
Randomised 
control trial 
181 premature 
cardiovascular 
disease patients 
 Among patients taking one or more 
antihypertensive drugs at recruitment 
(82%), a target blood pressure (<140/90 
mmHg) was achieved in only 37% patients 
with the TT genotype compared with 59% 
with the CT and 64% with the CC 
genotype (P < 0.001). 
 Riboflavin intervention reduced mean 
blood pressure specifically in those with 
the TT genotype (from 144/87 to 131/80 
mmHg; P<0.05 systolic; P<0.05 diastolic), 
with no response observed in the other 
genotype groups. 
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Although the decrease of tHcy concentration was already demonstrated in large-scale 
trials with folate supplementation, no blood pressure response was registered, 
supporting the idea that the direct involvement of Hcy is unlikely. On top of that, 
repairing 5-methylTHF levels, through riboflavin re-establishment of MTHFR function, 
may improve NO activity, lowering blood pressure. The decline of methylation status 
observed in patients with the TT genotype may also respond to riboflavin and could 
have an impact in blood pressure control. Thus, CVD risk associated with TT genotype 
could be explained with the relation between MTHFR 677C→T polymorphism and 
hypertension, leading to the invalidation of the application of Mendelian randomisation 
to the MTHFR 677C→T polymorphism, Hcy and CVD risk triangle (Wilson et al., 
2012). 
 
Current findings reinforce the benefits of personalised medicine, a topic vastly 
debated among the scientific community and clinical practitioners. Professionals 
sharing this view believe that the adjustment of medical interventions to specific 
individuals can markedly increase health. The 10% of the general population, and the 
higher proportions of some ethnic groups, who carry the TT genotype may profit from 
targeted treatment with riboflavin (Wilcken et al., 2003).  
 
As a final remark, studies seem to be more concordant about the impact of TT 
genotype on hypertension. Moreover, this genotype group seems to be responsive to 
riboflavin, especially in cases where conventional antihypertensive therapy is 
ineffective. Consequently, riboflavin could offer an affordable approach associated with 
antihypertensive drugs in hypertensive TT genotype patients. However, further studies 
need to be conducted to assure this association and the riboflavin benefit in 
hypertension treatment (Horigan et al., 2010).  
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CHAPTER IV – MTHFR 677C→T POLYMORPHISM, FOLATE AND CANCER 
 
4.1. GENE-NUTRITION INTERACTION AND EPIGENETICS ON CANCER 
Carcinogenesis is a molecular multistep process initiated by modifications in normal 
cellular mechanisms, such as DNA repair, cell cycle, apoptosis, differentiation, 
proliferation, hormonal regulation, inflammation and immunity [Fig. 16]. Failures in 
any of these mechanisms can conduct to genome rearrangements and instability, 
apoptosis inhibition, angiogenesis and biological active chemical induction. Changes in 
the expression of multiple genes happen not only due to genetic alterations, but also as a 
result of epigenetic changes, leading to activation of protooncogenes and prometastatic 
genes, or inactivation of tumour suppressor genes and anti-metastasis genes (Stefanska, 
2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epigenetics can be described as an inherited and/or self-propagated phenomenon 
affecting gene expression without altering the primary genomic sequence. It comprises 
mainly, DNA methylation, histone acetylation and methylation and non-coding RNA-
related mechanisms, caused by metabolic, nutritional and other environmental factors 
(Kim, Friso, & Choi, 2009). 
Figure 16. Shared acquired capabilities that enable malignant growth in human cancers (Hanahan & 
Weinberg, 2011). 
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DNA methylation is probably the best-understood epigenetic mechanism. The 
reaction is reversible and catalysed by a DNA methyltransferases, which transfer SAM 
methyl groups to the fifth position of a cytosine pyrimidine ring (Yoo & Jones, 2006). 
Global DNA hypomethylation together with hypermethylation of certain promoters, 
especially in the cytosine rich areas (known as CpG islands), have been discovered to 
take place both independently and in combination with each other. When acting 
simultaneously, global hypomethylation (translated in an increase of gene expression) 
has been suggested to occur as an initial stage in tumourigenesis, whereas promoter 
hypermethylation (translated in a reduction of gene expression) is a subsequent 
phenomenon, associated with the silencing of tumour suppressor and DNA repair genes 
(Jung, 2014). 
 
The interaction between epigenetics and nutrition, specially “low-methyl” diet, in 
affecting cancer in humans is an emerging area of research and DNA methylation has 
been confirmed to be affected by nutrition in neoplastic alterations (Lee, 2009). Folate 
and one-carbon metabolism are linked to cancer risk through their fundamental role in 
DNA synthesis and methylation. An interesting model of gene-nutrient
 
interaction in 
phenotypic expression is patent in MTHFR 677C→T polymorphism and has been 
associated with risk of several cancers in epidemiological studies. Dietary folate may 
differentially alter the effect of MTHFR 677C→T polymorphism, increasing or 
decreasing cancer risk (Hubner & Houlston, 2008). 
 
Two mechanisms have been suggested by which folate deficiency could have an 
impact on carcinogenesis [Fig. 17]. On one hand, folate deficiency involves a decrease 
in available 5-methylTHF, which originates a reduction in the conversion of Hcy to 
methionine, reducing the availability of SAM and consequently, leading to global 
hypomethylation, gene-specific hypomethylation and possibly activation of proto-
oncogenes (Stefanska, 2012). On the other hand, insufficient folate availability during 
mitosis can lead to a lower production of thymidine, inducing uracil misincorporation 
into DNA. Failures in the attempt to repair DNA can increase the frequency DNA 
strand breakage and chromosome damage. Even though evidences in support of these 
mechanisms are limited, it has been shown that low folate originates micronuclei 
(suggestive of chromosome breakage) and that the TT genotype leads to increased 
micronuclei formation under low folate conditions (Crider et al., 2012). 
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The carcinogenesis of breast cancer in premenopausal women, gastric cancer, 
bladder cancer, esophageal cancer may be more associated to genome hypomethylation, 
while the carcinogenesis of prostate cancer and colorectal cancer may be more 
correlated to DNA synthesis (Jin, Qu & Shen, 2009). 
 
 
 
 
Figure 17. Decreased dietary folate intake markedly perturbs both DNA methylation and 
biosynthesis (adapted from: Lamprecht & Lipkin, 2003). 
 
 
Several observational studies have suggested a causal role of MTHFR 677C→T 
polymorphism, low folate intake and impaired folate metabolism in cancer progression. 
Numerous evidences indicate that this gene-diet interaction might be involved in the 
development of many types of cancer [Table 9] (Bai et al., 2009; Larsson et al., 2006). 
 
So far, results from recent meta-analyses are not unanimous showing different 
degrees within the association between MTHFR 677C→T polymorphism and cancer 
risk. On one hand, results demonstrate a statistically significant association. On the 
other hand, some suggest that the polymorphism has low-penetrance susceptibility or 
may even be protective against cancer risk in TT genotype individuals. This situation 
can be related to the role of folate in modulating carcinogenesis, and reinforce the need 
to incorporate data on folate intake when interpreting results of MTHFR 677C→T 
polymorphism in relation to cancer risk (Bai et al., 2009; Zhang et al., 2010).  
 
CANCER 
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Table 9. Results from studies relating cancer and MTHFR 677C→T polymorphism. 
Cancer / Authors Results / Conclusions 
Prostate cancer 
 
Bai et al., 2009 
Meta-analysis of 3511 cases and 2762 controls 
• T allele was more likely to exert a protective effect on prostate cancer risk 
(OR = 0.81, 95% CI: 0.68–0.98) with a recessive genetic model. 
• No association was found for the CT genotype and the TT homozygote with 
prostate cancer risk compared with CC, with OR = 1.13 (95% CI: 0.88–1.45) 
and OR = 0.85 (95% CI: 0.71–1.03), respectively. 
 MTHFR 677C→T polymorphism is a low-penetrance susceptibility 
gene for prostate cancer, and might provide protective effects against 
prostate cancer risk. 
Hepatocellular 
carcinoma (HCC) 
 
Fabris et al., 2009 
Cohort of patients transplanted for end stage liver disease 
• Among the 65 patients with HCC, 22 had the CC genotype, 30 the CT, and 13 
the TT genotype. 
• Only in patients with alcoholic liver disease was a significant association 
detected between the TT genotype and the presence of liver cancer. 
• At stepwise logistic regression analysis, the independent selected predictors 
of HCC were found: age at transplantation >55 years (p < 0.001) and the 
association among male gender, alcoholic liver disease, and TT genotype (p = 
0.002). 
 Male TT carriers with alcoholic cirrhosis bear an increased risk of 
developing HCC. 
Esophageal, Gastric, 
and Pancreatic 
Cancer 
 
Larsson et al., 2006 
Systematic review with meta-analysis of epidemiologic studies 
• The summary relative risks for the highest versus the lowest category of 
dietary folate intake were 0.66 (95% CI, 0.53–0.83) for esophageal squamous 
cell carcinoma (4 case-control), 0.50 (95% CI, 0.39–0.65) for esophageal 
adenocarcinoma (3 case-control), and 0.49 (95% CI, 0.35–0.67) for pancreatic 
cancer (1 case-control, 4 cohort). 
• In most studies, the TT genotype was associated with an increased risk of 
esophageal squamous cell carcinoma, gastric cardia adenocarcinoma, noncardia 
gastric cancer, gastric cancer, and pancreatic cancer; all but one of 22 OR were 
>1, of which 13 estimates were statistically significant. 
 Folate may play a role in carcinogenesis of the esophagus, stomach, and 
pancreas. 
Breast cancer 
 
Zhang et al., 2010 
Meta-analysis involving 15,260 cases and 20,411 controls 
• Significantly elevated breast cancer risk was associated with TT genotype in 
homozygote comparison and dominant genetic model (TT vs. CC: OR = 1.11, 
95% CI = 1.01–1.23; dominant model: OR = 1.04, 95% CI = 1.00–1.09). 
• In the subgroup analysis by ethnicity, significantly increased risks were found 
for TT allele carriers among Asians (TT vs. CC: OR = 1.18, 95% CI = 1.04–
1.35; recessive model: OR = 1.15, 95% CI = 1.03–1.29). 
• When stratified by study design, statistically significantly elevated risk was 
found in hospital-based studies (TT vs. CC: OR = 1.18, 95% CI = 1.02–1.38; 
recessive model: OR = 1.17, 95% CI = 1.05–1.29). 
• In the subgroup analysis by menopausal status, statistically significantly 
increased risk was found among postmenopausal women (CT vs. CC: OR = 
1.12, 95% CI = 1.02–1.23; dominant model: OR = 1.11, 95% CI = 1.01–1.22). 
 MTHFR T allele is a low-penetrant risk factor for developing breast 
cancer. 
Childhood acute 
lymphocytic 
leukaemia 
(ALL) 
 
Franco et al., 2001 
Case-control 
• MTHFR 677C→T polymorphism was detected in 34 patients (48%) and in 49 
control subjects (69%), yielding an overall OR for ALL of 0,4 (95% CI 0,2–
0,8). OR for heterozygotes was 0,5 (95% CI 0,2–0,9) and for homozygotes the 
OR was 0,3 (95% CI 0,09–0,8). 
 The polymorphism was linked to a significant 2,4-fold decreased risk of 
developing childhood ALL. 
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An important characteristic of these studies that assure reliable results is 
stratification. Some meta-analyses that have stratified studies by design showed 
significantly elevated risk in hospital-based studies (Zhang et al., 2010). Hospital 
patients are likely to have different features than the population, for instance, they may 
have higher levels of alcohol ingestion, tend to be smokers, or be nutritional 
imbalanced, features that are related to cancer risk, which may result in biased results 
(Morabia, Stellman & Wynder, 1996). 
  
Although randomised controlled trials are more applicable to disclose association 
between folate and cancer risk, observational studies turn out to be used more 
frequently, due to ethical issues. Thus, observational nutritional studies are more 
difficulty to get reliable results from, because the evaluation of the actual amounts of 
folate consumed by individuals is very inaccurate, and is almost impossible to control 
other nutrients in the diet that may have an impact on the association between folate and 
cancer risk (Byers, 1999). 
 
When stratification was made regarding ethnicity, the great majority of studies have 
revealed significantly increased cancer risk for TT allele carriers among Asian, while in 
Caucasians this association was, in most cases, not very statistically significant 
(Zintzaras, 2006).  
 
Surprisingly, the great amount of studies regarding cancer risk and MTHFR 
677C→T polymorphism were conducted in China and there is a pronounced unanimity 
among results when compared to studies conducted in Western countries. The high 
frequency of the T allele (Yang et al., 2013), the high incidence of cancer and the fact 
that 20% of the population is considered to be folate deficient in China, might be the 
causes for the rise of studies about the relation between MTHFR 677C→T 
polymorphism and cancer risk (Song et al., 2001). Since the major pool of studies has 
been conducted in China, it is imperative to stratify by ethnicity, while conducting a 
meta-analysis, to avoid worldwide erroneous extrapolations of results (Szumilas, 2010). 
 
 
 
Folic acid, one-carbon metabolism, MTHFR polymorphisms and pathologies 
 
52 
4.2. FOLATE AND COLORECTAL CANCER 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men and 
the second in women and is strongly characterised by biochemical and genetic pathways 
associated with diet and lifestyles. The process by which CRC progresses comprises an 
accumulation of genetic mutations in tumour suppressor and proto-oncogenes genes, 
mainly APC, K-Ras and p53, leading to an adenoma that can reach a carcinoma stage 
[Fig. 18]. Moreover, several epigenetic modifications are associated with the 
development of CRC, such as genomic global hypomethylation, gene promoter region 
hypermethylation, histone modifications and alteration of miRNA patterns (Fearon, 
2011). 
 
 
 
 
Figure 18. Steps in the development of sporadically occurring cancer in a normal colon epithelium. 
Not all colorectal tumours exhibit all the mutations presented above (adapted from: Davies, Miller & 
Coleman, 2005; Fearon, 2011). 
 
Chemoprevention with bioactive food components has been supported by several 
studies as a result of risk reduction in CRC. Due to evidences from epidemiological 
studies pointing to a modest protection against CRC, folate has been contemplated as a 
chemopreventive candidate and the relation with CRC risk has been vastly scrutinised 
(Guerreiro et al., 2008).  
 
Although some short-term trials do not confirm this association, others suggest that a 
long latency period (15 years or more) of folate supplementation is required for a 
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significant 75% risk reduction in CRC. This association has been found mostly in colon 
rather than rectum cancer (Hubner & Houlston, 2008). The mechanism is thought to be 
related with decrease misincorporation of uracil into DNA, as described in the previous 
section. In contrast to cardiovascular risk, HHcy has not been linked to CRC (Van 
Guelpen et al., 2006). 
 
However, a dual effect of folate in CRC has been reported. This duality involves 
timing, the amount and the type of folate consumed. If the supplementation is 
implemented before the establishment of the neoplasia, a protective effect is noticed. 
Conversely, if an increased intake of folate starts once CRC is already present folate can 
have a detrimental effect. Some evidences suggest that nutritionally adequate baseline 
folate status has a positive effect in reducing CRC risk, whereas excessive intake or 
fortification and supplements of synthetic folic acid can fuel the growth of neoplastic 
cells. In agreement with this idea, mice models genetically predisposed to develop 
tumours showed increased microscopic lesions when fed with folic acid supplements 
[Fig. 19] (Castillo-Lancellotti, Marí & Dagach, 2012). 
 
 
Figure 19. Dual effect of folate supplementation in the risk of colorectal cancer (adapted from: 
Du, Li, Lu & Fang, 2010). 
 
Several mechanisms regarding this duality have been proposed. folic acid differently 
from folate in diet has to be reduced before it can be metabolised. In cases of increased 
intake of folic acid the enzyme responsible for the reduction can easily saturate leading 
to elevated plasma levels of unmetabolised folic acid. Thus, the circulating folic acid 
can be channelized directly to nucleotides synthesis increasing proliferation of 
precancerous cells and promoting tumourigenic processes (Williams, 2012). 
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Another suggestion is that the beneficial effect reported mainly for folate, present in 
the diet, can be due to the interaction with other food compounds. Furthermore, there is 
a possibility that folate may interact with other risk factors, such as smoking, alcohol 
consumption, diet, physical activity, and hormone-related factors in a “folate-
independent pathway” influencing the carcinogenesis process (Chuang et al., 2013). 
Finally, a recent study revealed that moderate dietary folate depletion decreases the 
expression of genes involved in pro-inflammatory and immune-related pathways, 
whereas repletion or supplementation have the opposite effect in most cases (Protiva et 
al., 2011). 
 
4.3. MTHFR 677C→T POLYMORPHISM AND COLORECTAL CANCER  
The intricacy between folate and CRC risk is enhanced by the presence of functional 
polymorphisms. Studies point to a selective advantage for TT genotype carriers, 
suggesting a 12% reduced risk of CRC compared to heterozygous genotype and wild-
type.  However, under circumstances of high total folate intake, the associated risk of 
CRC is equally reduced for both CC and TT genotypes. The association has been found 
mainly in colon, rather than in rectum cancer, particularly at a later stage (Kennedy et 
al., 2012).  
 
Low intake diets of methyl groups, such as high alcohol consumption (folate 
antagonist interfering with folate absorption), low in folate, choline and methionine 
(important dietary sources of methyl groups) have been associated with increased risk of 
CRC. The risk of CRC through the combination of high alcohol-low folate and the TT 
genotype is thought to be related to epigenetics [Fig. 20]. In cases of low folate-high 
alcohol status, the MTHFR 677C→T polymorphism may increase the risk of elevated 
DNA hypomethylation. Conversely, TT genotype, in combination with balanced folate 
status and low alcohol, could allow a larger pool of 5, 10-methyleneTHF for 
thymidylate synthesis and therefore decrease uracil misincorporation and consequent 
chromosome breakage, reducing the risk of CRC (Giovannucci, 2004). 
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Figure 20. Interactions between high alcohol-low folate, TT genotype and risk of colorectal cancer 
(adapted from: Giovannucci, 2004). 
 
Nonetheless, recent publications still reveal conflicting results [Table 10]. One meta-
analysis conducted in 2012 showed that MTHFR 677C→T polymorphism contributes to 
the decreased CRC risk in overall population (Kennedy et al., 2012). Another meta-
analysis, performed in 2013, found that MTHFR 677C→T polymorphism is a potential 
risk factor of CRC in overall populations, except among African descent population. 
However, only four studies in African populations were included in this meta-analysis 
(Teng et al., 2013).  
 
Comparison of high versus low folate intake within the genotype can help shed light 
on inconsistent results about this subject. In fact, a study conducted in the Portuguese 
population indicates that conditions of low folate intake, can lead to an increased risk of 
CRC in the TT genotype. Authors suggested that the lack of folic acid fortification and 
the low use of vitamin supplements, which is characteristic in many countries, might 
lead to a relatively low folate intake (Guerreiro et al., 2008). This fact could explain the 
association between TT genotype and increased risk of CRC. 
 
Although meta-analyses have been employed to assess the link between MTHFR 
677C→T polymorphism and CRC risk, the quality of single studies incorporated may 
differ considerably. For example, the studies that are conducted in different countries 
can represent different sources of folate and different food choice combinations, 
increasing the heterogeneity of the results. Then, publication bias may occur because 
only published studies are included in the majority of meta-analysis. In addition, the 
selection of individuals in control group in some studies is based only on the lack of 
symptoms, not excluding latent cancer cases. Apart from that, in some studies, 
interactions between MTHFR 677C→T polymorphism and some environmental risk 
Dysregulates  
gene expression 
↓ uracil 
misincorporation 
into DNA 
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factors are not entirely explored, along with the risk of gene-gene or linkage 
disequilibrium between other polymorphisms (Teng et al., 2013).  
 
Table 10. Results from studies relating colorectal cancer risk, folate and MTHFR 677C→T 
polymorphism. 
Authors Study design Results 
Guerreiro et 
al., 2008 
Case-control 
 
196 patients with CRC 
and 200 healthy controls 
matched for age and sex 
were evaluated for intake 
of methyl-donor 
nutrients and the 
polymorphism. 
• Except for folate intake, which was significantly lower 
in patients (P = 0.02), no differences were observed in the 
dietary intake of other methyl-donor nutrients between 
groups.  
• High intake of folate (>406.7 μg/d) was associated with 
a significantly lower risk of CRC (odds ratio: 0.67; 95% 
CI: 0.45, 0.99).  
• In contrast, TT genotype presented a 3,0-fold increased 
risk of CRC (95% CI: 1.3, 6.7).  
• Low intake of all methyl-donor nutrients was associated 
with an increased risk of CRC in TT genotype, but a 
statistically significant interaction was only observed for 
folate (odds ratio: 14.0; 95% CI: 1.8, 108.5).  
Kennedy et al., 
2012 
Systematic Review 
and Meta-Analysis 
 
10 observational studies 
were included which 
assessed the risk of CRC 
for the polymorphism 
and/or had defined levels 
of folate intake for the 
polymorphism and 
assessed the risk of CRC. 
• The summary risk estimate comparing the CT versus 
CC genotype was 1.02 (95% CI 0.95–1.10) and for TT 
versus CC was 0.88 (95% CI 0.80–0.96) both with 
heterogeneity. 
• The summary risk estimate for high versus low total 
folate for the CC genotype was 0.70 (95% CI 0.56–0.89) 
and the TT genotype 0.63 (95% CI 0.41–0.97). 
• TT genotype is associated with a reduced risk of 
developing CRC, under conditions of high total folate 
intake, and this associated risk remains reduced for both 
CC and TT genotypes. 
Teng et al., 
2013 
Meta-Analysis 
 
71 publications 
including 31,572 cases 
and 44,066 controls 
• MTHFR 677C→T polymorphism is significantly 
associated with increased risk of colorectal cancer. 
• In the stratified analysis by ethnicity, significantly 
increased risks were also found among: 
→ Caucasians for CC vs TT (OR = 1.076; 95%CI = 
1.008–1.150; I2 = 52.3%), CT vs TT (OR = 1.102; 95%CI 
= 1.032–1.177; I2 = 51.4%) and dominant model (OR = 
1.086; 95%CI = 1.021–1.156; I2 = 53.6%).  
→ Asians for CC vs TT (OR = 1.226; 95%CI = 1.116–
1.346; I
2
 = 55.3%), CT vs TT (OR = 1.180; 95%CI = 
1.079–1.291; I2 = 36.2%), recessive (OR = 1.069; 95%CI 
= 1.003-1.140; I
2
 = 30.9%) and dominant model (OR = 
1.198; 95%CI = 1.101-1.303; I
2
 = 52.4%). 
→ Mixed populations for CT vs TT (OR = 1.142; 95%CI 
= 1.005-1.296; I
2
 = 0.0%).  
- No associations were found in Africans for all genetic 
models. 
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In 2012, a comparison of approaches for association studies of polymorphisms and 
CRC risk was conducted. From this analysis, authors assumed that there is variation in 
calculated relative risk and changes in tests for publication bias that were dependent on 
the inclusion criteria used for association studies of polymorphisms and CRC. Thus, 
normalising study inclusion conditions may decrease the variation in findings for meta-
analyses of gene-association studies of CRC (Ramsey et al., 2012). 
 
Recently, the role of riboflavin has been also explored. Some studies suggest that 
high intake of riboflavin may enhance folate protective effect in colorectal adenomas, 
which seems to be more significant in TT genotype individuals [Fig. 21a]. In an in vitro 
study, the decrease of nuclear buds (a marker of gene amplification), through the 
increase of folic acid concentration was greater in the presence of high levels of 
riboflavin. Furthermore, a randomised, placebo-controlled trial, stratified by the 
genotype was performed in individuals with normal mucosa and in those with 
adenomatous polyps. Subjects were randomly given placebo, low folic acid, low folic 
acid plus riboflavin, or high folic acid. Results showed that riboflavin administration 
boosted the systemic response to low-dose folic acid in polyp patients, particularly in 
TT and CT genotypes [Fig. 21b] (Powers, 2005).  
 
 
a)      b) 
   
 
Figure 21. Interaction among folate, riboflavin, genotype, and colorectal cancer. a) Interaction 
between MTHFR 677C→T polymorphism (CC, CT, TT, genotypes) and riboflavin intake in risk 
of CRC; b) effect of riboflavin administered with low-dose folic acid in determining plasma folate 
concentration in patients (CT, TT, genotypes) with adenomatous polyps (Powers, 2005). 
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One can hypothesize that, as cofactor of MTHFR, low riboflavin intake along with 
folate deficiency could increase uracil misincorporation and decrease 5-methylTHF 
availability for Hcy remethylation, leading to dysregulation of gene expression through 
epigenetic mechanisms. By contrast, high concentrations of riboflavin could moderately 
balance enzyme activity in heterozygotes and homozygotes when folate concentrations 
are low. Thus, not only folate, but also riboflavin could protect against MTHFR 
thermolability and, therefore, help reduce the risk of CRC. 
 
4.4. MTHFR 677C→T POLYMORPHISM AND CHEMOTHERAPY IN COLORECTAL 
CANCER  
In conjunction with chemoprevention, the attention drawn to folate metabolism is 
due to its possible interference in pharmacodynamics of anticancer agents. One of the 
most common chemotherapeutic agents used in CRC is 5-fluorouracil (5-FU). 
Nonetheless, the standard chemotherapy used in adjuvant and advanced CRC comprises 
several regimens along with the simple 5-FU based treatment, such as 5-FU-folinic 
modulation, FU combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI), and 
the associations of FU-containing chemotherapies with biological targeted therapies 
(Etienne‐Grimaldi et al., 2010).  
 
To optimize response rate, prognosis and to minimize the side effects associated to 
chemotherapy treatments, some predictive factors have been investigated. 5-FU, an 
antimetabolite acting as a TYMS inhibitor, requires concentrations of 5, 10-
methyleneTHF. The 5-FU active metabolite fluorodeoxyuridine monophosphate 
(FdUMP) binds to the nucleotide-binding site of TYMS and forms a stable ternary 
complex with TYMS and 5, 10-methyleneTHF, blocking access of dUMP to the 
nucleotide-binding site and inhibiting dTMP synthesis. This results in deoxynucleotide 
(dNTP) pool imbalances and increased levels of deoxyuridine triphosphate (dUTP), 
causing DNA damage [Fig. 22] (Longley, Harkin & Johnston, 2003). 
 
Elevated concentrations of 5, 10-methyleneTHF are dependent on MTHFR enzyme 
activity, opening the possibility for a correlation between the MTHFR 677C→T 
polymorphism and cancer response to FU-based chemotherapy. Thus, increase 
intracellular folate concentrations in conjunction with MTHFR 677C→T polymorphism 
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would increase the availability of 5, 10-methyleneTHF and therefore would improve 
sensitivity to fluoropyrimidines (Sharma et al., 2008). 
 
 
 
Figure 22. Mechanism of thymidylate synthase inhibition by 5-fluorouracil (adapted from: Longley, 
Harkin & Johnston, 2003). 
 
 
The research carried out in this field is relatively recent and the results found are 
inconsistent. Some findings suggest that the type of chemotherapy treatment used can 
have an impact on the predictive effect of MTHFR 677C→T polymorphism, with TT 
genotype patients having a better response to 5-FU monotherapies, in comparison with 
combined therapy such as, FOLFOX or FOLFIRI. Furthermore, MTHFR 677C→T 
polymorphism was found to be considerably associated with toxicity, particularly with 
grade 3 or 4 diarrhoea after FOLFOX administration (Chua et al., 2009). 
  
Based on the current knowledge, it would be very premature to agree with an 
established association between MTHFR 677C→T polymorphism and CRC treatment, 
centred only in the small and conflicting evidences. Nonetheless, pharmacogenomics 
can be a useful tool to optimize the selection of the chemotherapy regimen according to 
the genomic profile of the patient, highlighting the need for prospective and larger 
cohort studies to reach consistent results about MTHFR 677C→T polymorphism and 
the response to 5-FU in CRC treatment. 
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4.5. MTHFR: AN ALTERNATIVE IN ANTI-TUMOUR THERAPY. 
MTHFR has been investigated as a potential new strategy for cancer chemotherapy. 
Due to the need for methionine by transformed cells, disruption of methionine cycle 
through MTHFR inhibition could be useful for cancer therapy. Some in vitro and in vivo 
studies demonstrated that antisense-mediated inhibition of MTHFR can lead to 
cytotoxicity, and, consequently, reduced progression of human cancer cells.  Antisense-
mediated inhibition is a transfection technic of antisense oligonucleotides (ASOs), such 
as EX5 or 677T, commonly used to downregulate the expression of genes in tumour 
cells. ASOs form RNA-DNA duplexes, causing a decrease in the gene expression. 
MTHFR antisense was showed to lead to a decrease in cell survival by 70% (EX5) or 
80% (677T) in the colon and breast carcinoma lines and in neuroblastoma (Sekhon et 
al., 2002).  
 
Another in vivo study demonstrated that the combination of MTHFR antisense-
mediated inhibition with cytotoxic drugs, such as 5-FU and cisplatin has a potentiated 
effect on inhibiting cell growth. EX5 inhibited the growth of human colon carcinoma 
xenografts, by 90%, in combination with 5-FU, 40% more when compared with EX5 
alone. In combination with cisplatin, EX5 decreased the growth of lung tumours 
xenografts by 85%, an additional 40% compared with cisplatin alone (Stankova, Shang 
& Rozen, 2005).  
 
The mechanism underlying growth inhibition by EX5 can be linked to low 
concentrations of MTHFR enzyme and to apoptosis. MTHFR inhibition can cause DNA 
hypomethylation, contributing to gene expression changes that might affect cell growth. 
Moreover, MTHFR inhibition can lead to elevated tHcy, which promotes apoptosis 
through oxidative stress enhancement, as demonstrated in some cell cultures (Stankova, 
Shang & Rozen, 2005). Thus, MTHFR downregulation approach seems to be a 
promising alternative route in cancer treatment. 
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CONCLUSIONS 
 
In summary, the function of folate in one-carbon metabolism efficiency has been 
demonstrated, which is extremely depend on the total tetrahydrofolate cofactors pool, 
and tightly regulated by different feedback loops. Additionally, MTHFR 677C→T 
polymorphism seems to be a significant co-determinant involved in plasma 
homocysteine levels, DNA synthesis and methylation, particularly when folate levels 
are low, and should be integrated into the multifaceted role of folate in the prevention of 
disease. Thus, the interaction between the MTHFR gene and folate is a robust example 
of a gene-nutrient interaction (Ueland et al., 2001). 
 
The explanation behind the geographical and ethnic distribution of the MTHFR 
677C→T polymorphism remains hypothetical. Additional assessment of gene-nutrition, 
medical, and nutritional factors involving MTHFR 677C→T polymorphism, along with 
improved understanding of human demographic history is necessary to elucidate its 
high frequency and extensive distribution. A better comprehension would encourage 
specific preventive measures that could be conducted in specific ethnicities, such as 
public-health education, emphasizing the impact of balanced folic and B-vitamin 
consumption (Guéant-Rodriguez et al, 2006). 
 
In addition, the association between MTHFR 677C→T polymorphism and 
cardiovascular disease, through plasma homocysteine has been found in many 
observational studies (Xuan et al., 2011). Nevertheless, recent evidences seem to point 
towards the hypothesis that increased plasma homocysteine is indeed an 
epiphenomenon (Clarke et al., 2012), although the topic remains an open question, 
without scathing and unanimous results, with the possible exception of stroke (Li & 
Qin, 2014).  
 
One should contemplate that hyperhomocysteinemia could result from other diverse 
genetic and biological conditions, and that cardiovascular disease is directly linked to 
this particular conditions leading to the elevation of plasma homocysteine, confounding 
the results (Ueland & Loscalzo, 2012). Furthermore, an alternative mechanism of 
MTHFR 677C→T polymorphism, independent from homocysteine cannot be totally 
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dismissed, jeopardizing the foundation of Mendelian randomisation when reviewing 
this association (Ueland et al., 2000). Further research is need to understand the 
mechanisms underlying MTHFR 677C→T polymorphism and cardiovascular health. 
 
Even though, hyperhomocysteinemia do not seem to be a casual factor for 
cardiovascular disease, we could still consider plasma homocysteine elevation as 
biomarker, predictor of cardiovascular disease, and MTHFR 677C→T polymorphism 
could be equally determined as a measure in public health (Den Heijer, Lewington & 
Clarke, 2005). However, according to evidences from several meta-analysis concerning 
the implication of interactions between MTHFR 677C→T polymorphism, tHcy levels 
and cardiovascular disease it would be precipitate to propose such procedure. Moreover, 
the negative results in secondary-intervention studies have demonstrated no benefit 
from supplementation with folic acid in patients with established cardiovascular disease 
(Clarke et al., 2012). An intervention that decreases the biomarker without modifying 
the disease incidence is worthless; therefore, folic acid supplementation for 
cardiovascular patients without evident vitamin deficiency cannot be encouraged.  
 
Another fact that cannot be rejected is the discrepancy observed between meta-
analyses of published Mendelian randomisation studies that could be attributed to 
several methodological problems, but publication bias might seems to be the large 
source of discrepancies. Some studies may have been chosen for publication due to their 
positive results in favour of others that reveal negative results (Haynes & Clarke, 2012).  
 
Regarding hypertension, although the exact mechanism linking MTHFR 677C→T 
polymorphism to hypertension is yet to be fully understood, it seems that higher blood 
pressure in individuals with the TT genotype is adjustable by correcting the variant of 
the MTHFR enzyme by riboflavin status improvement. Consequently, supplementation 
of riboflavin in this genetic group, could present a personalized approach to the 
treatment of hypertension (Horigan et al., 2010). Nevertheless, more prospective, 
double-blind, randomized studies, including riboflavin intervention, hypertension and 
MTHFR 677C→T polymorphism should be conducted. 
 
Another important remark is the role of genetic factors, such as MTHFR 677C→T 
polymorphism in carcinogenesis, along with explicit evidences that environmental 
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factors, such folate, are crucial in defining cancer risk. Therefore, several studies have 
shown that the TT genotype is related to biomarkers, such as global DNA methylation 
particularly in a low folate diet, confirming that the reduce availability of folate can lead 
to exacerbation of genetic variations in MTHFR enzyme function (Crider et al., 2012). 
Therefore, different dietary habits among populations could be the source 
inconsistencies in findings from molecular epidemiologic studies relating cancer risk 
and MTHFR 677C→T polymorphism (Guerreiro et al., 2008).  
 
Taking together, the great majority of studies suggest that high supply of folate and 
TT genotype carriers may have a lower risk to develop colorectal cancer, particularly 
colon cancer, since adequate intake reduces the imbalance in the synthesis of 
nucleotides, assuring the correct DNA replication (Kennedy et al., 2012). However, this 
may not hold true for all populations, due to the different degrees of folate consumption 
(Teng et al., 2014). A genetic and environmental risk assessment for colorectal cancer 
risk in primary care, regarding folate and MTHFR 677C→T polymorphism is worth 
considering (Hall et al., 2012). 
 
Currently, evidences indicate that differences in the type and amount of folates, 
along with colorectal cancer onset may increase the risk for developing adenomas and 
colorectal cancer, forcing the re-evaluation of criteria and levels of folic acid 
supplementation in some populations. Thus, scientific evidences are not solid enough to 
recommend folate supplementation in populations at risk for colorectal cancer. Further 
research on gene-environment interactions is compulsory to define the association 
between increased intake of folate and colorectal cancer (Castillo-Lancellotti, Marí & 
Dagach, 2012).  
 
Further studies should focus on less well studied populations, such as Africans. Other 
combinations of polymorphisms in MTHFR gene and its prevalence should also be 
considered in persons with different levels of intake of dietary factors, along with the 
research of possible explanatory mechanisms (Lee, 2009). Additionally, folate and 
riboflavin interaction on the MTHFR 677C→T polymorphism should be further 
investigated, due to recent findings that support the beneficial effect of riboflavin in 
modulating folate levels (Powers, 2005).  
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Furthermore, MTHFR 677C→T polymorphism seems to have a pharmacogenetic 
role in the response estimation of some chemotherapy protocols, allowing another step 
in the direction of personalized therapy. Clinicians could use genetic tests to assess 
which patient carries the variant of MTHFR gene, which can be associated, in theory, 
with better prognosis, and also less side effects to the 5-fluorouracil monotherapy 
regimen. If proved, these findings could offer an adjustment in the concentrations of 5-
fluorouracil chemotherapy regimens in patients without a beneficial MTHFR genotype. 
However, the overall of recent studies do not seem to be consistent regarding this issue 
(Chua et al., 2009). Thus, more large-scale human studies of combined polymorphisms 
from MTHFR gene may result in a more efficient method than single polymorphism 
studies. 
 
Finally, the comprehension of MTHFR polymorphism mechanisms was essential for 
the development of new alternative anti-cancer drugs (Sekhon et al., 2002). Recent 
research on MTHFR inhibition technique is showing promising results as a potential 
anti-cancer therapy, through the increased response of cancer cells to some cytotoxic 
drugs. The confirmation of this finding, apart from the additive or synergistic effect 
with the standard anti-cancer drugs, could allow the reduction of their concentrations, 
minimizing toxicity and drug resistance (Stankova, Shang & Rozen, 2005). 
 
The findings from this review could serve as background information of MTHFR 
677C→T polymorphism for future epidemiologic studies on cardiovascular disease, 
colorectal cancer, and on the involvement of MTHFR gene in cancer treatment.
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